Gastroenterology and Hepatology: Recent Episodes
ReachMD
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Brennan Spiegel, MD, MSHS
With colorectal cancer screening rates still lagging, blood-based liquid biopsy tests are emerging as a promising strategy to improve adherence, especially among those reluctant to undergo traditional screening methods. However, these tests come with some challenges that may limit their real-world effectiveness. Joining Dr. Charles Turck to discuss these potential benefits and barriers is Dr. Brennan Spiegel, a Professor of Medicine in Public Health and the Director of Health Services Research at Cedar-Sinai in Los Angeles.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David Fudman, MD
As the advanced treatment landscape for irritable bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn’s disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Samuel Muench, MD
With colorectal cancer screening rates still falling short of national goals, new strategies are gaining attention—particularly blood-based tests. A recent modeling study compared this emerging tool to other options like stool-based testing and colonoscopy, exploring its potential as a colorectal cancer screening method and barriers to its adoption. Joining Dr. Charles Turck to break down the study and discuss the role of blood-based screening tests in shaping the colorectal cancer screening landscape is Dr. Samuel Muench. Dr. Muench is a board-certified and fellowship-trained gastroenterologist at Capital Digestive Care in Washington, DC.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Stefan Holubar, MD, MS
When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn’s disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jane McElroy, PhD
Guest: Jean Wang, MD, PhD
Guest: Nuha Wareg, MPH, MBBS
Colorectal cancer screening remains underutilized across several underserved populations, including racial minorities and rural communities. That’s why Dr. Charles Turck speaks with Drs. Jane McElroy, Jean Wang, and Nuha Wareg to learn about practical, evidence-based strategies we can implement to improve screening uptake, reduce disparities, and promote high-quality, equitable care. Dr. McElroy is a Professor in the University of Missouri’s Family and Community Medicine Department and the Co-Director of its Rural Health Research Center, Dr. Wang is a Professor of Medicine and Surgery in the Division of Gastroenterology at Washington University School of Medicine, and Dr. Wareg serves as a Practice Facilitator for the Missouri Partnership to Improve Colorectal Cancer Screening program at the University of Missouri.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Mark Benson, MD
Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.
Host: Brian P. McDonough, MD, FAAFP
Guest: Carolyn Rutter, PhD
Guest: Gloria Coronado, PhD
Colorectal cancer screening strategies have significantly evolved in recent years, with noninvasive options like stool and blood-based tests explored for their potential to boost adherence. Drs. Gloria Coronado and Carolyn Rutter join Dr. Brian McDonough to evaluate how these methods compare to traditional colonoscopy in terms of cost-effectiveness, accessibility, and their ability to overcome screening barriers, particularly in underserved populations. Dr. Coronado is a Professor of Epidemiology and the Associate Director of Population Science for the University of Arizona Cancer Center, and Dr. Rutter is a Professor in the Biostatistics Program and Principal Investigator for a Cancer Intervention and Surveillance Modeling Network team at Fred Hutchinson Cancer Center.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: J. Andy Tau, MD
Topical hemostatic agents play a key role in managing complex bleeding cases, but there’s a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michael Dougherty, MD
Rural populations face unique challenges in accessing colorectal cancer screening, leaving many patients in these communities unscreened. However, mailed fecal immunochemical testing (FIT) may help address these barriers and improve adherence. Joining Dr. Peter Buch to discuss the benefits and limitations associated with FIT and its potential impact on the colorectal cancer screening landscape is Dr. Michael Dougherty. Dr. Dougherty is an Adjunct Assistant Professor in the Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: A. Mark Fendrick, MD
Colorectal cancer screening saves lives—but how do common methods like colonoscopy and non-invasive screening methods compare in their environmental effects? With the healthcare sector being responsible for over four percent of the global carbon footprint, researchers are looking into more environmentally friendly options that can still provide optimal outcomes for patients. Dr. Peter Buch sits down with Dr. Mark Fendrick to examine the carbon footprint of available colorectal cancer screening strategies and explore how a shift to noninvasive options could offer promising clinical and environmental impacts. Dr. Fendrick is a Professor of Internal Medicine and Health Management and Policy at the University of Michigan.
Host: Brian P. McDonough, MD, FAAFP
Guest: Sheila Reddy, MD
Guest: Carol M. Antequera, DMSc, PA-C
When treating patients with irritable bowel syndrome with diarrhea (IBS-D), primary care providers have a variety of pharmacologic or behavioral options to choose from. Creating a personalized, integrative care plan can help address symptoms and maintain patient well-being. Join Dr. Brian McDonough, Dr. Sheila Reddy, and Ms. Carol Antequera as they share their perspectives on individualizing IBS-D care and facilitating communication with patients. Dr. Reddy is a board-certified gastroenterologist at Austin Gastroenterology in Texas, and Ms. Antequera is a physician assistant specializing in gastroenterology at the University of Miami Health System in Florida.
Salix Pharmaceuticals
400 Somerset Corporate Blvd.
Bridgewater, NJ 08807
© 2025 Salix Pharmaceuticals or its affiliates. MED-US-NPR-0060
Host: Harry Yoon, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Guest: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.
Host: Brian P. McDonough, MD, FAAFP
Guest: Holly S. Greenwald, MD
Misconceptions around irritable bowel syndrome with diarrhea (IBS-D) can contribute to significant gaps in care and unmet patient needs. Primary care providers play a crucial role in addressing these needs and ensuring an accurate diagnosis. To learn more about best practices for diagnosing and communicating with patients, Dr. Brian McDonough sits down with Dr. Holly Greenwald, Assistant Professor of Clinical Medicine at Temple University Lewis Katz School of Medicine.
Salix Pharmaceuticals
400 Somerset Corporate Blvd.
Bridgewater, NJ 08807
© 2025 Salix Pharmaceuticals or its affiliates. MED-US-NPR-0048
Host: Brian P. McDonough, MD, FAAFP
Guest: Paul P. Doghramji, MD, FAAFP
For patients with IBS-D, the stigma surrounding the condition can make it difficult to openly discuss their symptoms and accept their diagnosis. Providing reassurance and a clear path forward can help create a supportive and comfortable environment for these patients. To learn more about how we can destigmatize IBS-D, Dr. Brian McDonough sits down with Dr. Paul Doghramji, who’s the Medical Director of Health Services at Ursinus College and a physician at Collegeville Family Practice and Pottstown Memorial Medical Center.
Salix Pharmaceuticals
400 Somerset Corporate Blvd.
Bridgewater, NJ 08807
© 2025 Salix Pharmaceuticals or its affiliates. MED-US-NPR-0053
Guest: Sara Horst, MD, MPH, FACG
While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.
Guest: Elisa K. Boden, MD
For many patients with Crohn’s disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn’s and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
Guest: Elisa K. Boden, MD
For patients with Crohn’s disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
Guest: Shalini Prasad, PhD
Guest: Sriram Muthukumar, PhD
Host: Charles Turck, PharmD, BCPS, BCCCP
With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: William Chey, MD
Recent changes to the American College of Gastroenterology’s guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Vivek Kaul, MD
The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David P. Hudesman, MD
Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone’s Inflammatory Bowel Disease Center.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David P. Hudesman, MD
With so many therapeutic options for Crohn’s disease and ulcerative colitis, it can be challenging to determine which one best matches your patient’s needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic landscape for inflammatory bowel disease.
Host: Harry Yoon, MD
Guest: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Mary E. Rinella, MD, FAASLD
Guest: Naga Chalasani, MD, FAASLD
Guest: Mazen Noureddin, MD, MHSc
Join us for a CME online broadcast replay of a live satellite symposium from ACG 2024, where experts discuss MASLD/MASH, a serious disease that is both chronic and progressive. What’s most concerning is that MASLD/MASH will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Until recently there was no liver-directed therapy for this disease, and the metabolic benefits of pharmacologic modification of body weight were underappreciated. This activity will also provide practical interactive discussions of cardiometabolic pathophysiologic pathways; early identification and risk stratification; advances in treatment; monitoring for disease progression; and long-term medical management, including the role of incretin agonists.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
While neuromodulators are primarily used to treat psychiatric disorders, they can also help normalize symptoms of irritable bowel syndrome by targeting the gut-brain axis. In fact, about half of all patients with IBS have the potential to benefit from neuromodulators. Dr. Douglass Drossman joins Dr. Peter Buch to discuss his research on how various neuromodulators can provide relief for IBS patients. Dr. Drossman is the President of the Drossman Center of Education and Practice of Psychosocial Care and Drossman Consulting as well as a Professor Emeritus of Medicine and Psychiatry at the University of North Carolina School of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Steven Maron, MD, MSc
Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.
References:
- The Cancer Genome Atlas Network. Nature. 2014;513:202-209.
- Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125.
- Yang B, et al. J Exp Clin Cancer Res. 2019;38:283.
- American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024.
- Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082.
©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sara Enslin, PA
Current colorectal cancer (CRC) screening rates are low, putting patients at risk of developing more advanced disease and even increased mortality. Primary care physicians play a critical role in reversing this troubling trend, which is why Dr. Charles Turck speaks with Ms. Sarah Enslin about strategies for improving adherence to CRC screening in the primary care setting. Ms. Enslin is a physician assistant at the University of Rochester Medical Center in Rochester, New York.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: William Grady, MD
While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kyle Staller, MD, MPH
Join Dr. Peter Buch as he speaks with Dr. Kyle Staller, Director of the Gastrointestinal Motility Laboratory at Mass General and Assistant Professor of Medicine at Harvard Medical School, about uncovering the cause of a patient’s bloating and determining how to manage it.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kyle Staller, MD, MPH
The complexities of gastroparesis can make the disease difficult to diagnose and treat. To help us overcome these challenges, Dr. Kyle Staller joins Dr. Peter Buch to share his preferred strategies for managing patients with gastroparesis. Not only is Dr. Staller an Assistant Professor of Medicine at Harvard University, but he’s also the Director of the GI Motility Lab at the Massachusetts General Hospital.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eamonn Quigley, MD
Small intestinal bacterial overgrowth (SIBO) is often overdiagnosed due to misconceptions about symptoms and inaccurate tests. Join Dr. Peter Buch and Dr. Eamonn Quigley as they explore considerations for knowing when and how to diagnose and treat SIBO. Dr. Quigley is the Chief of Gastroenterology and Hepatology and the Co-Director of the Lynda K. and David M. Underwood Center for Digestive Disorders at Houston Methodist Hospital.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Brian E. Lacy, MD, PhD
About 50 percent of gastrointestinal providers are experiencing some degree of burnout, which can lead to a variety of personal and professional challenges. Joining Dr. Peter Buch to discuss the signs of burnout and what you can do to mitigate them is Dr. Brian Lacy, lead author of the “Burnout in Gastrointestinal Providers” article published in the American Journal of Gastroenterology in 2024.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Edward L. Barnes, MD, MPH
Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders. Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders. Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders.
Host: Matt Birnholz, MD
The United States Preventative Services Task Force endorses multiple screening options for patients at average-risk of colorectal cancer (CRC). These options include colonoscopy, multi-target stool DNA, and the fecal immunochemical test. However, performance data for non-endorsed options like multi-target stool RNA and blood-based screening tests have recently been published. That’s why a recent poster presented at the 2024 Digestive Disease Week conference compared the benefit-to-harm ratio for guideline-endorsed versus non-endorsed CRC screening tests. Tune in to learn more about the findings and their implications for CRC screening.
Host: Matt Birnholz, MD
For patients at average risk of colorectal cancer (CRC), the United States Preventative Services Task Force recommends screening with either the multi-target stool DNA test or fecal immunochemical test. But in light of new performance data that compared a multi-target stool DNA test and a fecal immunochemical test, a poster presented at the 2024 Digestive Disease Week conference re-evaluated the benefits and harms associated with each test. Tune in to learn more about the findings and their implications for CRC screening.
Host: Jennifer Caudle, DO
Guest: A. Mark Fendrick, MD
Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn the details of this study and how we can incorporate the findings into practice, join Dr. Jennifer Caudle as she speaks with Dr. Mark Fendrick, Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jasmohan Bajaj, MD
Around 50 percent of people with cirrhosis have hepatic encephalopathy, which means some kind of brain dysfunction. As these patients age, it gets more and more difficult to differentiate between hepatic encephalopathy and dementia, which is why two recent studies sought to uncover how many patients with dementia have undiagnosed cirrhosis. According to the findings, the rate of undiagnosed cirrhosis and hepatic encephalopathy could be as high as 10‒13 percent. Joining Dr. Charles Turck to share further details about the studies, findings, and implications is Dr. Jasmohan Bajaj, Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Naga Chalasani, MD
It’s recommended that if patients with cirrhosis are using acetaminophen long-term, it should be a limited dosage. But should we be avoiding nonsteroidals in patients with decompensation cirrhosis? To walk through the impacts of analgesics in patients with cirrhosis, join Dr. Peter Buch as he speaks with Dr. Naga Chalasani, David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That’s why a team with the HCC Steering Committee of the Chronic Liver Disease Foundation developed a web-based, interactive tool that incorporates current guideline recommendations to help clinicians diagnose and treat patients with hepatocellular carcinoma. To learn more about this tool, Dr. Jody Takemoto speaks with Dr. Robert Wong. Not only is he a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine, but he also helped develop the tool.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
Hepatitis B is one of the leading causes of liver cancer globally, underscoring the importance of screening, diagnosing, and treating patients appropriately. However, there are several considerations to keep in mind when caring for patients with hepatocellular carcinoma with hepatitis B co-infection, which is why Dr. Jody Takemoto speaks with Dr. Robert Wong about those factors and essential management strategies. Dr. Wong is a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
A recent study explored clinician-level gaps and barriers to hepatocellular carcinoma surveillance in patients with cirrhosis and found that there is a lot of work to be done to help improve knowledge about cirrhosis, the recommended cancer screening guidelines, and how to implement those recommendations. Joining Dr. Jody Takemoto to discuss these findings and how we can address the uncovered challenges is Dr. Robert Wong, Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine.
Host: Jody Takemoto, PhD
Guest: Bryson Katona, MD, PhD
At the 2024 Digestive Disease Week Annual Meeting, Dr. Bryson Katona presented a session, titled “High-Risk Colon Cancer: The ABCs of Genetic Testing.” And now, Dr. Katona is here with Dr. Jody Takemoto to share key insights from his session on genetic testing for patients with high-risk colon cancer. Dr. Katona is the Director of the Gastrointestinal Cancer Genetics Program and Risk Evaluation Program and the Lynch Syndrome Program at Penn Medicine
Guest: Andres J. Yarur, MD
Obesity has recently surfaced as an important topic in patients with inflammatory bowel diseases, such as Crohn’s and ulcerative colitis, but historically, these patients have been underweight. This led to the phase III pivotal trials for the use of upadacitinib in patients with moderate to severe ulcerative colitis and Crohn’s disease to see how their baseline BMI would influence the efficacy of the drug. To hear the details and findings of this study, join Dr. Andres Yarur, Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California. He also presented this study at Digestive Disease Week 2024.
Guest: Andres J. Yarur, MD
Health maintenance emphasizes health promotion and disease prevention, which is very important for patients with inflammatory bowel disease (IBD) since they’re at an increased risk of several life-threatening conditions. Tune in to hear Dr. Andres Yarur discuss essential health maintenance strategies for patients with IBD. Dr. Yarur is an Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michael Camilleri, MD
When it comes to irritable bowel syndrome (IBS), it’s important to keep in mind that there are certain diagnoses clinicians can make to specifically treat the underlying problem that’s causing the symptoms that suggest IBS. To learn more about these complex mimickers, join Dr. Peter Buch as he speaks with Dr. Michael Camilleri, Professor of Medicine at the Mayo Clinic College of Medicine and Science.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David P. Hudesman, MD
There’s been an increase in the elderly irritable bowel disease (IBD) population, and it’s estimated that a third of our overall IBD population will soon be over the age of 60. When managing and diagnosing these patients, there’s different factors to consider, like polypharmacy, biological versus chronological age, how fit these patients are versus how frail they are, and more. To take a deep dive into how IBD is affecting elderly patients, join Dr. Peter Buch as he speaks with Dr. David Hudesman, Professor of Medicine and Co-director of NYU Langone’s Inflammatory Bowel Disease Center.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Francis Farraye, MD
Patients with inflammatory bowel disease (IBD) have an increased risk of developing infections, and some may be preventable with a vaccine. Approximately 70 percent of patients with ulcerative colitis or Crohn’s disease will be on immunosuppressive therapy at some point during their treatment course, so it’s best to try to address vaccines before they’re immunosuppressed. So to walk us through some strategies for increasing the number of patients with gastrointestinal diseases who get vaccinated, Dr. Peter Buch is joined by Dr. Farraye, Co-Author of the article, titled “How to Implement a Successful Vaccination Program in Outpatient Gastroenterology Practices: A Focus on Patients with Inflammatory Bowel Disease and Chronic Liver Disease,” which appeared in Gastroenterology in 2023 and Professor of Medicine at the Mayo Clinic in Jacksonville, Florida, where he also directs the Inflammatory Bowel Disease Center.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Alexander Ford, MD
Irritable bowel syndrome (IBS) is diagnosed using the ROME 4 criteria, and fortunately, most patients who meet the criteria for IBS clinically are unlikely to have another underlying explanation for their symptoms. However, a common misconception is that IBS is a diagnosis of exclusion, so to learn more about this and other controversies surrounding IBS, join Dr. Peter Buch as he speaks with Dr. Alexander Ford, Professor of Gastroenterology and Honorary Consultant of Gastroenterology at Leeds Institute of Medical Research at St. James University of Leeds.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David Wan, MD
Many patients with lower gastrointestinal (GI) bleeding are on anticoagulants, and they may need specific reversal agents depending on what antithrombotic they’re on. Tune into this episode to learn more about the article that dives into the management and treatment of acute lower GI bleeding and the challenges along the way with Dr. Peter Buch as he speaks with Dr. David Wan, Associate Professor of Medicine at New York-Presbyterian/Weill Cornell Medical Center.
Host: Cem Akin, MD, PhD
Guest: Daniel J. DeAngelo, MD, PhD
New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.
Host: Cem Akin, MD, PhD
Guest: Daniel J. DeAngelo, MD, PhD
Guest: Matthew J. Hamilton, MD
Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of care for ISM and discuss why allergists, hematologists, and gastroenterologists are at the vanguard of this change.
Host: Tauseef Ali, MD, FACG, AGAF
Host: Sabina Ali, MD
Host: Neil Nandi, MD, FACP
Host: Tina Aswani-Omprakash, MPH
A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.
Host: Arun B. Jesudian, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Patricia P. Bloom, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Patricia P. Bloom, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Patricia P. Bloom, MD
Host: Robert Rahimi, MD, MSCR
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Robert Rahimi, MD, MSCR
Host: Arun B. Jesudian, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Arun B. Jesudian, MD
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Robert Rahimi, MD, MSCR
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Arun B. Jesudian, MD
Host: Robert Rahimi, MD, MSCR
Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Andrew Keaveny, MD
Guest: Don Rockey, MD
Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Samuel J. Klempner, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Samuel J. Klempner, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Marlyn Mayo, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Atoosa Rabiee, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Marlyn Mayo, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Atoosa Rabiee, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Marlyn Mayo, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Atoosa Rabiee, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Marlyn Mayo, MD
Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Guest: Atoosa Rabiee, MD
Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
Host: Kimberly A. Brown, MD
This chairman’s perspective highlights the role of gastroenterologists in improving patient care and outcomes and will increase their awareness of NAFLD/NASH. Dr. Kimberly Brown takes a deep dive into late-stage clinical trials to address unmet clinical needs and the potential for new agents to address these needs. Gastroenterologists will benefit from reviewing the safety and efficacy data, as it will help prepare them to quickly integrate new agents into their practice when they become available.
Guest: Alan C. Moss, MD, FACG, FEBG, AGAF, FRCPI
Guest: Sophie M. Balzora, MD
Guest: Latonia Ward, M.Min
The goal of this program is to improve the overall management of patients with ulcerative colitis (UC). Specifically, we aim to improve clinician knowledge and competence with respect to the novel mechanisms of action of sphingosine-1-phosphate receptor (S1P) modulators and Janus kinase (JAK) inhibitors and their respective roles in the overall treatment paradigm of UC. We also aim to improve patient-centered approaches to the management of UC with a particular focus on underserved communities and Black, Indigenous, and people of color (BIPOC). To bolster our commitment to these patient populations, Boston University Chobanian & Avedisian School of Medicine partnered with Color of Crohn’s & Chronic Illness (COCCI) for this initiative.
Endorsed by the AGA Institute
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Vinay Sehgal, MBChB, MRCP, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Adrian R. Parry-Jones, FRCP, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Martin Möckel, MD, PhD
Host: Richard Body, MB ChB, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Natalie Kreitzer, MD, MS
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Vinay Sehgal, MBChB, MRCP, PhD
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Susann Järhult, MD
Host: Martin Möckel, MD, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Tobias Lindner, MD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Tobias Lindner, MD
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Susann Järhult, MD
Host: Richard Body, MB ChB, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Natalie Kreitzer, MD, MS
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Susann Järhult, MD
Host: Martin Möckel, MD, PhD
This program focuses on the management of life-threatening bleeds from a range of specialties: Emergency Medicine, Neurocritical Care, Trauma, and Gastroenterology. A panel of international Emergency Medicine experts will provide perspectives on each of the associated areas of bleeding and relevant clinical cases.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
Guest: Alan H.B. Wu, PhD
Liver disease patients are at an increased risk of major adverse cardiovascular events (MACE), which is why the doctor in today’s episode believes the multidisciplinary team plays an essential role in managing these patients. Tune in with Dr. Charles Turck as he speaks with Dr. Zobair Younossi, Chair of the Global NASH Council and Professor of Medicine at the Inova Fairfax Medical Campus in Falls Church, Virginia as well as Dr. Alan Wu, Professor in Laboratory Medicine and is Chief of the Clinical Chemistry and Toxicology Laboratories at San Francisco General Hospital.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: John Pandolfino, MD, MSCI
There are a wide range of therapeutic options when it comes to personalizing your patient’s treatment approach, such as simple lifestyle modifications all the way to a surgical procedure. To learn more, tune in with Dr. Peter Buch as he speaks with Dr. John Pandolfino, Hans Popper Professor and Chief of Gastroenterology and Hepatology in the Department of Medicine at Northwestern Medicine Feinberg School of Medicine in Chicago.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Siddharth Singh, MD
How can we use biomarkers to treat patients with ulcerative colitis? That’s the exact question the latest guideline from the American Gastroenterological Association (AGA) sought to address. Learn about this guideline and other best practices with Dr. Peter Buch and Dr. Siddharth Singh, Assistant Professor of Medicine at the University of California-San Diego and co-author of an article published in Gastroenterology in March 2023 titled “AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.”
Host: John Buse, MD, PhD
Guest: Karen D. Corbin, PhD, RD
One of the biggest missing links in current literature about obesity and the gut microbiome was causality. In an effort to address that gap, a recent clinical trial was conducted, and now, the results are in. So what were the key findings, and how can we translate those findings into clinical practice? Find out how one’s diet can affect the gut microbiome with Dr. John Buse and Dr. Karen Corbin, an Investigator at the AdventHealth Translational Research Institute in Orlando, Florida.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Alan Bonder, MD
According to the United Network for Organ Sharing (UNOS), more than 95 percent of patients are alive and doing well after a liver transplant. So what else can we learn from UNOS? Join Dr. Peter Buch as he speaks with Dr. Alan Bonder, Assistant Professor of Medicine at Harvard Medical School.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Suijit Janardhan, MD, PhD
Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they’re particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush University Medical Center in Chicago.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kunal Jajoo, MD
The American Gastroenterological Association (AGA) recently published updated clinical guidelines for the use of endoscopic ultrasound (EUS). Are there caveats involved with these recommendations? Join Dr. Peter Buch as he speaks with Dr. Kunal Jajoo, Assistant Professor of Medicine at Harvard Medical School, about the best utilization of EUS in clinical practice.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Herbert L. Bonkovsky, MD
If an elevation of delta aminolevulinic or porphobilinogen occurs in the urine more than three times what is normal, that is presumptive acute hepatic porphyria (AHP. Join the conversation as Dr. Peter Buch speaks with Dr. Herbert Bonkovsky, Professor of Medicine and Molecular Medicine and Translational Science at Wake Forest University, about his article published in Gastroenterology.
Host: John L. Marshall, MD
Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairman’s Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI Cancer in Barcelona, Spain, so you can more effectively treat your patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Sidney Barritt, MD
Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That’s why Dr. Peter Buch speaks with Dr. Sidney Barritt about top treatment strategies for nonalcoholic fatty liver disease in part one of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the Director of Hepatology at the UNC Liver Center at the University of North Carolina.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Sidney Barritt, MD
Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That’s why Dr. Peter Buch speaks with Dr. Sidney Barritt about even more treatment strategies for nonalcoholic fatty liver disease in the second and final part of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the Director of Hepatology at the UNC Liver Center at the University of North Carolina.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gil Melmed, MD, MS
The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program.
References:
-
US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/135612/download
-
US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/82647/download
©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Marianna Arvanitakis, MD, PhD
Consuming ultra-processed foods can pose many risks to your health that go beyond the GI system. Explore the risks associated with ultra-processed foods with Dr. Peter Buch and Dr. Marianna Arvanitakis, Associate Clinical Professor in the Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology from the HUB Erasme Hospital in Brussels, Belgium.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Claire Jansson-Knodell, MD
When a person has a low IgA level, the tissue transglutaminase immunoglobulin A antibody is no longer a useful screening test for celiac disease. So how should we be assessing patients with an IgA deficiency? To discuss these new recommendations, Dr. Peter Buch is joined by Dr. Claire Jansson-Knodell, Gastroenterologist at the Cleveland Clinic’s Digestive Disease Institute.
Guest: Bruce E. Sands, MD, MS
An expert in IBD discusses the latest in early diagnosis, individualizing therapy, and monitoring of IBD. Hear about early signs and symptoms of IBD as well as strategies for individualizing initial therapy in patients with IBD based on available agents and guidelines.
Guest: Bruce E. Sands, MD, MS
In this brief medical minute, Bruce E. Sands, MD, MS, an expert in IBD discusses the clinical challenges of IBD management including biologic failure and surgical management.
Guest: Abigail Meyers, PA-C
In this brief medical minute, Abigail Meyers, PA-C, an expert in IBD, discusses strategies to address the clinical challenges of IBD management during pregnancy and engaging patients in shared decision-making.
Guest: Bruce E. Sands, MD, MS
In this short medical minute, Bruce E. Sands, MD, MS, an expert in IBD management, discusses the latest in treat-to-target and therapeutic drug monitoring in patients with IBD.
Guest: Ryan Ungaro, MD, MS
This Medical Minute will discuss how to identify and target objective measures of ulcerative colitis disease activity to achieve mucosal healing.
Guest: Bruce E. Sands, MD, MS
Guest: Abigail Meyers, PA-C
In this brief medical minute, two experts in IBD, Abigail Meyers, PA-C and Bruce E. Sands, MD, MS, discuss collaborative and holistic care for IBD management.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michael Camilleri, MD
Metoclopramide is the only FDA-approved medication for the treatment of gastroparesis; however, it comes with a black box warning. To discuss the challenges in diagnosing and treating gastroparesis, Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine, Pharmacology, and Physiology at the Mayo Clinic in Rochester, Minnesota.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Alan Bonder, MD
According to this clinician, the most important thing for primary biliary cholangitis (PBC) patients is the diagnosis, and anyone with abnormal liver tests should be sent an antimitochondrial antibody (AMA). Dive into this interview with host Dr. Peter Buch and Dr. Alan Bonder, Assistant Professor of Medicine and the Medical Director of Liver Transplantation at Beth Israel Medical Center in Boston.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Shelby Yaceczko, MS, RDN-AP, CNSC
The burden of malnutrition across the globe is very high, with hospitals and care teams being directly impacted. Here with Dr. Mary Katherine Cheeley to share what we need to know about the relationship between nutritional deficiencies and health economics in the hospital is Ms. Shelby Yaceczko, an Assistant Clinical Professor in the Department of Nutrition at the University of the Pacific in Sacramento, California.
Host: Dawn Adams, MD
Discover best practices for taking a collaborative, multidisciplinary approach to nutritional care with Dr. Dawn Adams, Medical Director for the Center for Human Nutrition at Vanderbilt University Medical Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Dejan Micic, MD
Early intervention is key when it comes to optimizing outcomes among patients suffering from malnutrition. Explore best practices for identifying and treating adult malnutrition with Dr. Charles Turck and Dr. Dejan Micic, Associate Professor of Medicine at UChicago Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Kwo, MD
Hepatitis B and C are both highly prevalent infections around the world. However, many individuals are not aware of their infection, which can lead to progressive liver damage and other health consequences. This is just one of the many unmet needs in the hepatitis care continuum, and joining Dr. Charles Turck to help uncover those unmet needs and discuss how the latest management strategies can help address them is Dr. Paul Kwo, Director of Hepatology at Stanford University.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Scott D. Isaacs, MD FACP, FACE
Since type 2 diabetes is the number one risk factor for the progression to advanced liver fibrosis, monitoring diabetic patients is absolutely critical, especially considering the fact that the symptoms of disease progression can be nonexistent or very vague. Here with Dr. Mary Katherine Cheeley to break down the latest guidelines and strategies for monitoring liver health in patients with diabetes is endocrinologist Dr. Scott D. Isaacs.
Host: Mazen Noureddin, MD
Nonalcoholic steatohepatitis (NASH) is an epidemic with enormous health and economic implications. Join us for our chairman’s perspective on best practices to identify, screen, and refer patients. Dr. Mazen Noureddin also examines some of the emerging therapeutics that may change your approach to NASH.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Carolyn Newberry, MD
Commercially blenderized and standard tube feeding formulas are both ways we can deliver food to our patients requiring home enteral nutrition. So how do these two types of formulas stack up against one another? Find out with Dr. Charles Turck as he discusses the latest literature findings and other key considerations with Dr. Carolyn Newberry, Director of GI Nutrition at Weill Cornell Medical Center’s Division of Gastroenterology.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kunal Jajoo, MD
Clinicians should be assessing their patients immediately and trying to understand how quickly they need to provide endoscopy and endoscopic therapy. So in patients with a high risk for thromboembolism, how soon after GI bleeding may anticoagulation be considered? Take a deep dive with Dr. Peter Buch as he speaks with Dr. Kunal Jajoo, Assistant Professor of Medicine at the Brigham and Women’s Hospital of Harvard Medical School.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Alan Bonder, MD
Patients with underlying autoimmune diseases could be at a higher risk of developing autoimmune hepatitis (AIH). So what challenges might occur when diagnosing patients with AIH? Learn more with Dr. Peter Buch as he discusses this with Dr. Alan Bonder, Director of Liver Transplantation at Beth Israel Deaconess Hospital and an Assistant Professor of Medicine at Harvard Medical School.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Robert Wong, MD
There may be benefit in testing all hepatitis B patients for hepatitis D, such as reducing the risk of disease progression and liver disease complications. So when should we be concerned about potential hepatitis D infection in our patients? Join Dr. Peter Buch as he discusses this with Dr. Robert Wong, Clinical Associate Professor at Stanford University.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Neil Sengupta, MD
Lower GI bleeding is one of the most common reasons that patients are hospitalized due to a digestive disorder in the U.S.; however, there is little data available to help clinicians manage this condition in their patients. So how can we provide better care for these patients? Tune in with Dr. Peter Buch as he speaks with Dr. Neil Sengupta, Associate Professor of Medicine at the University of Chicago.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eamonn Quigley, MD
A new treatment option may help relieve chronic constipation in patients who might not respond well to traditional therapies. To learn more about a novel FDA-approved vibrating capsule, join Dr. Peter Buch as he speaks with Dr. Eamonn Quigley, the David M. Underwood Chair of Medicine in Digestive Disorders and a Professor of Medicine at Houston Methodist.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Osman Mohamed Elfadil, MD
Food allergies and malabsorptive conditions limit food options for patients and can lead to malnutrition if alternative sources of nutrition aren’t found. So how might peptide-based formulations fit into our management approach for these GI-compromised patients? Joining Dr. Charles Turck to break down how peptide-based formulations work to improve GI tolerance, who might benefit from them, and the latest data from clinical trials is Dr. Osman Mohamed Elfadil, Senior Research Fellow in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition at the Mayo Clinic in Rochester, Minnesota.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Anna Nowak-Wegrzyn, MD
Cow’s milk protein allergy is one of the most common food allergies in childhood and can have a heavy burden on our young patients and their families. That’s why Dr. Charles Turck speaks with Dr. Anna Nowak-Wegrzyn, Director of the Pediatric Allergy Program at Hassenfeld Children’s Hospital NYU Langone, about how we can better manage these patients and address their unmet needs.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Joel Rubenstein, M.D., M.Sc.
Gastroesophageal reflux disease (GERD) is an important risk factor for Barrett’s esophagus and esophageal adenocarcinoma (EAC), but there are other important risk factors, such as gender and race. So is it time to look at alternative approaches to increase appropriate screenings? Join Dr. Peter Buch as he is joined by Dr. Joel Rubenstein, Research Scientist at the Kettles VA in Ann Arbor, Michigan and a Professor of Internal Medicine in the Department of Gastroenterology and Hepatology at the University of Michigan School of Medicine.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Amit Singal, MD, MS
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and most often occurs in people with chronic liver disease. So should we be utilizing modalities other than standard ultrasound for routine early detection of HCC in cirrhotic patients? Listen to this discussion led by Dr. Peter Buch as he speaks with Dr. Amit Singal, Professor of Medicine and the Chief of Hepatology at the University of Texas Southwestern Medical Center.
Host: Marshall Miller
This episode of Rub Some Dirt in It is getting curiouser and curiouser. See if you can solve these two cases before host Marshall Miller reveals the rare and unexpected diagnoses.
Host: Darren Brenner, MD
Host: Brooks D. Cash, MD, AGAF, FACG, FASGE
Despite advances in the treatment of irritable bowel syndrome with constipation (IBS-C), many patients are still struggling. Our experts, Drs. Darren Brenner and Brooks Cash, discuss the complexity of this condition, its diagnosis, treatment recommendations, and clinical trial data. Tune in to be sure you’re using all of the tools at your disposal to improve your patients’ quality of life.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: W. Frank Peacock, MD
For patients with opioid-induced constipation (OIC), can Narcan play a role in finding a new treatment option? Dr. Charles Turck is joined by Dr. Frank Peacock from the Baylor College of Medicine to explore key data on the role of methylnaltrexone in the treatment of OIC.
Host: Tanios S. Bekaii-Saab, MD
Guest: Joleen M. Hubbard, MD
Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer? Listen in as Drs. Tanios Bekii-Saab and Joleen Hubbard talk about the recent approval of tucatinib and trastuzumab for the treatment of HER2-positive metastatic CRC and other therapies in development.
Host: Neilanjan Nandi, MD
Guest: Monika Fischer, MD
Clostridioides difficile, or C. difficile for short, is a bacteria that continues to plague our patients. What are the latest treatment updates that you need to be aware of? Dr. Neil Nandi is joined by Dr. Monika Fischer from Indiana University to dive into treatment options and discuss the latest updates.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Brooks D. Cash, MD, AGAF, FACG, FASGE
Acute colonic pseudo-obstruction, also known as Ogilvie’s syndrome, is a rare form of colonic dilatation that can be serious and life-threatening. To learn more about this disorder, Dr. Peter Buch and Dr. Brooks Cash take a look at risk factors, testing strategies, and treatment options for Ogilvie’s syndrome.
Host: Lisa B. Malter, MD
As the landscape of inflammatory bowel disease (IBD) patients is changing, it’s important for healthcare professionals to be aware of the diversity in patient populations and how to best serve them. That’s why the first component of this two-part webinar features gastroenterologist Dr. Lisa B. Malter, who discusses common myths surrounding IBD in certain populations and evidence-based treatment strategies for different patient groups. She’s also joined by Rocio and Tara, two patients living with IBD who share their experiences with IBD management and treatment.
Host: Freddy Caldera, DO
Guest: Stacy A Ogbeide, PSYD, ABPP, CSOWM
Guest: Shubha Bhat, PharmD, MS, BCACP
Guest: Lisa B. Malter, MD
What cultural and cognitive biases might be contributing to health disparities in inflammatory bowel disease (IBD) care? And how can we address them? Find out in the second component of this two-part webinar featuring Drs. Freddy Caldera, Lisa B. Malter, Shubha Bhat, and Stacy Ogbeide. Together, they’ll discuss methods that can help facilitate open communication and strategies for overcoming health disparities in IBD care.
Host: Neilanjan Nandi, MD
Guest: Megan E. Riehl, PsyD
In an age where there’s an app for everything, are smartphone apps and other technology-enable solutions revolutionizing mental health treatment in patients with GI challenges? Dr. Neil Nandi speaks with Dr. Megan Riehl from the University of Michigan to explore the capabilities of these technologies and their role in treatment.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Maurizio Bonacini, MD
Patients with cirrhosis of the liver are typically more susceptible to portal vein thrombosis (PVT). So how can we provide the best care to our PVT patients? To find out, Dr. Peter Buch is joined by Dr. Maurizio Bonacini, CEO of Mission Gastroenterology and Hepatology and Associate Clinical Professor of Medicine at the University of California, San Francisco.
Host: Neilanjan Nandi, MD
Guest: Gursimran Kochhar, MD
What do the guideline updates recommend for the endoscopic treatment of Crohn’s disease strictures? Dr. Neil Nandi speaks with one of the guideline authors, Dr. Gursimran Kochhar from the Allegheny Health Network in Pittsburgh, Pennsylvania, to better understand how to manage these strictures.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: John Pandolfino, MD, MSCI
From bird beaking to functional lumen imaging probes (FLIP), what do we need to know about the presentation and treatment of achalasia? Dr. Peter Buch speaks with Dr. John Pandolfino from the Feinberg School of Medicine at Northwestern University about the various treatment options available for achalasia.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Brennan Spiegel, MD, MSHS
The pathogenesis of irritable bowel syndrome (IBS) remains unclear, but according to one professor, gravity may play a bigger role in this condition than we think. Dr. Peter Buch sits down with Dr. Brennen Spiegel from the Cedars Sinai Center for Outcomes Research and Education to dive into his research on gravitational management systems and IBS.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kyle Staller, MD, MPH
Chronic abdominal pain can be caused by many things—including hereditary angioedema (HAE). Are there any barriers to diagnosing patients with HAE? Dr. Peter Buch speaks with Dr. Kyle Staller from the Gastrointestinal Motility Laboratory at Mass General to explore the differential diagnosis for HAE and share what clinicians should be on the lookout for.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Jawad Ahmad, MD
Drug-induced liver injury (DILI) is a common problem for patients who take prescription medicine or herbal and dietary supplements. So what resources are available to help reduce this injury? Join Dr. Peter Buch as he speaks with Dr. Jawad Ahmad, Professor of Medicine at Icahn School of Medicine at Mount Sinai, to discuss his study and research on drug-induced liver injury.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kenneth Cusi, MD, FACP, FACE
From noninvasive tests to liver biopsies—what do we need to know about current diagnostic tools for nonalcoholic steatohepatitis (NASH)? Dr. Charles Turck joins Dr. Kenneth Cusi to dive into diagnostic guidelines and share the latest updates on these tools.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Paul Kwo, MD
Between 2.4 and 4.7 million people have hepatitis C in the United States, but not all have access to proper treatments. So how can clinicians reach more people in the community with this virus? Dr. Peter Buch will give us further insight with Dr. Paul Kwo, Professor of Medicine and the Director of Hepatology at Stanford University.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eugenia Shmidt, MD
The pregnancy inflammatory bowel disease and neonatal outcomes (PIANO) registry is the largest US-based study that examines pregnant women who have inflammatory bowel disease (IBD). So how can clinicians use the takeaways from this study in their practice? Join Dr. Peter Buch as he discusses IBD in pregnant women with Dr. Eugenia Shmidt, Assistant Professor in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Miguel Regueiro, MD
The horizon for patients with Crohn’s disease is looking promising as new treatments are expected to come out in the next few years. So what are the best practices for treating fistulizing Crohn’s disease? Explore the treatment landscape with Dr. Peter Buch and Dr. Miguel Regueiro, Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic.
Host: Ross M. Maltz, MD
Guest: Shail M. Govani, MD, MSc
Guest: Nana E. Bernasko, CRNP, WHNP-BC, DNP
Guest: Shubha Bhat, PharmD, MS, BCACP
As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Bryson Katona, MD, PhD
Lynch syndrome is the most common cause of inherited colon cancer and is often underdiagnosed. How can we improve detection of these patients? To find out more, Dr. Peter Buch joins Dr. Bryson Katona from the Hospital of the University of Pennsylvania to explore some key detection strategies.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Nancy S. Reau, MD
The most common liver disease caused by pregnancy is intrahepatic cholestasis of pregnancy (ICP). So what do clinicians need to know to best treat their patients? Explore the impact of liver disease on pregnancy as Dr. Peter Buch is joined by Dr. Nancy S. Reau, Professor in the Department of Internal Medicine at Rush Medical College.
Host: Sushila R. Dalal, MD
The management of inflammatory bowel disease (IBD) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Sushila Dalal presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
Host: Jenny S. Sauk, MD
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Sauk presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Arnold Wald, MD
The American Gastroenterological Association released updated guidelines for patients with irritable bowel syndrome with constipation (IBS-C). To find out more about the latest updates in treatment, Dr. Peter Buch dives into these guideline recommendations with Dr. Arnold Wald, a Professor of Medicine at the University of Wisconsin.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Paul Feuerstadt MD, FACG, AGAF
In the United States, about 80 percent of tests used to diagnose C. difficile are PCR assays. So what are the best options to diagnose and treat patients with this infection? To discuss the evolving treatment and evaluation landscape for C. difficile, Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor at Yale New Haven Hospital.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Robert Battat, MDCM, FRCPC
A kay cofounder in managing postoperative Crohn’s disease, bile acid diarrhea can be challenging to diagnose. What tests are currently available? To discuss this cofounder and how to diagnose it, Dr. Peter Buch sits down with Dr. Robert Battat, the Director of the Center for Clinical and Translational Research for Inflammatory Bowel Disease at the University of Montreal.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Robert Battat, MDCM, FRCPC
What confounders do we face when managing postoperative Crohn’s disease, and what tools do we have available to us? Dr. Peter Buch dives into this topic with Dr. Robert Battat, the Director of the Center for Clinical and Translational Research for Inflammatory Bowel Disease at the University of Montreal.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Daniel Strand, MD
Acute pancreatitis can be tricky to diagnose and treat. To help us understand how to better manage this condition, Dr. Peter Buch is joined by Dr. Daniel Strand, the Director of Pancreatobiliary Endoscopy at UVA Health in Charlottesville and an Associate Professor of GI Hepatology to share management updates for patients with recurrent acute and chronic pancreatitis.
Host: Neilanjan Nandi, MD
Guest: Andres Yarur, MD
Irritable bowel disease (IBD) often requires a personalized approach to treatment. So what does the current therapeutic drug monitoring landscape look like? Dr. Neil Nandi speaks with Dr. Andres Yarur, Associate Professor of Medicine at Cedars-Sinai in Los Angeles, about therapeutic drug monitoring for IBD.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Justin R Boike, MD, MPH
The procedure of transjugular intrahepatic portosystemic shunt (TIPS) is a crucial therapeutic option when treating patients with complications of portal hypertension. So what do we need to know about this procedure? To further delve into TIPS, Dr. Peter Buch is joined by Dr. Justin Boike, Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine.
Host: Richard S. Finn, MD
Guest: Peter R. Galle, MD
Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aline Charabaty, MD
Given what medications are currently available, inflammatory bowel disease (IBD) can be difficult to manage. What do we need to know about them, and how do we know which of our patients are the right candidates for them? To answer this question, Dr. Peter Buch speaks with Dr. Aline Charabaty from the Sibley Memorial Hospital.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Ira M. Jacobson, MD
What do the guidelines recommend for hepatitis B vaccination? Dr. Peter Buch joins Dr. Ira Jacobson, Director of Hepatology and Professor of Medicine at NYU Langone Health and NYU Grossman School of Medicine, to explore challenges and guidelines for hepatitis B vaccination.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
Adenoma detection rate (ADR) may help us better detect our patients’ risk of developing colorectal cancer. To explore what we need to know about this quality indicator, Dr. Peter Buch joins Dr. Aasma Shaukat from the New York University Grossman School of Medicine to talk about ADR.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Sara Horst, MD, MPH
Ulcerative colitis (UC) has an evolving treatment landscape, which has made it difficult for clinicians to position treatment options for their patients. What’s currently available? Dr. Peter Buch dives into this rapidly changing treatment landscape with Dr. Sara Horst, an Associate Professor at Vanderbilt University.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eamonn Quigley, MD
New recommendations about the pharmacological management of irritable bowel syndrome (IBS) with diarrhea by the American Gastroenterological Association (AGA) was published in Gastroenterology 2022. So what do we need to know about these updates, and which medications should we be using? To provide insight, Dr. Peter Buch is joined by Dr. Eamonn Quigley, the David M Underwood Chair of Medicine in Digestive Disorders and Professor of Medicine at the Academic Institute.
Host: Aparna R. Parikh, MD
Guest: Dustin Deming, MD
Guest: Scott Kopetz, MD, PhD
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
Host: Aparna R. Parikh, MD
Guest: Dustin Deming, MD
Guest: Scott Kopetz, MD, PhD
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David Leiman, MD, MSHP
Proton pump inhibitors (PPIs) are among the most commonly prescribed class of medication for acid-related disorders. But what are the long-term consequences of PPIs? And how have they changed the prescribing pattern among gastroenterologists? To help us better understand this topic, Dr. David Leiman, Assistant Professor of Medicine at Duke University School of Medicine, joins Dr. Peter Buch to discuss how we should be utilizing PPIs with our patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Benjamin L. Cohen, MD
Guest: Stefan Holubar, MD, MS
New data suggests that the use of anti-TNF therapy early in the treatment course can be effective for patients with inflammatory bowel disease (IBD). However, some of them may still require surgery. But is anti-TNF therapy safe in the perioperative period? To answer this question, Dr. Peter Buch is joined by Drs. Benjamin Cohen and Stefan Holubar from the Cleveland Clinic to discuss the findings from the PUCCINI study.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Victoria Gomez, MD
Endoscopic sleeve gastroplasty may be an effective option for weight loss. But which of our patients are the right candidates—and what do they need to know about before and after the procedure? Dr. Peter Buch dives into this procedure with Dr. Victoria Gomez, an Associate Professor of Medicine at the Mayo Clinic in Florida.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michel Kahaleh, MD
Endoscopic ultrasound-guided gallbladder drainage (ESU) is used to treat patients with cholecystitis and infection of the gallbladder. So when should we be utilizing ESU, and what are some common challenges associated with this procedure? Joining Dr. Peter Buch to explore this topic is Dr. Michel Kahaleh, Chief of Endoscopy, Director of the Pancreas Program, and Medical Director of the Advanced Endoscopy Research Program at Robert Wood Johnson Medical School.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Madhu Grover, MBBS
Gastroparesis is a complex disease that has limited treatment options. What do we need to know about it? Dr. Mandu Grover, an Associate Professor of Medicine at the Mayo Clinic, joins Dr. Peter Buch to discuss gastroparesis.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Madhu Grover, MBBS
Gastroparesis can be a complex disease to understand—and treat. What therapeutics are currently available? Dr. Peter Buch is joined by Dr. Mandu Grover, an Associate Professor of Medicine at the Mayo Clinic, to take a look at current treatment options.
Guest: Rishi D. Naik, MD, MSCI
Colorectal cancer may be more prevalent than you think, underscoring the importance of colorectal cancer screening. Join us as we explore the latest screening recommendations and available modalities with Dr. Rishi Naik, Assistant Professor of Medicine in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: Elizabeth Smyth, MD
Guest: Jaffer Ajani, MD
HER2 expression is a crucial biomarker when selecting treatment for patients with advanced gastric and gastroesophageal junction (GEJ) cancers. Until recently, there were limited therapeutic options. Join this lively conversation to enhance your knowledge related to emerging data and optimal treatment selection for patients with HER2-positive gastric and GEJ cancers.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Asma Khapra, MD
Over the last few years, we've only started to gain an understanding of how gender affects our approach to GI illnesses. And since a greater awareness of these differences will help us become better clinicians, Dr. Peter Buch speaks with Dr. Asma Khapra about how we can optimize our approach to managing common GI illnesses in our female patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Neilanjan Nandi, MD
Guest: Peter D. Higgins, MDm PhD
What's on the horizon for the management of inflammatory bowel disease? To share some of the latest clinical trial updates, Dr. Neil Nandi is joined by Dr. Peter Higgins from the University of Michigan to explore some of the latest developments in early detection tools and treatment strategies for patients with IBD.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Peter D. Higgins, MDm PhD
What were some of the key takeaways from the 2022 Crohn's & Colitis Congress, and what's in store for next year’s conference? Hear from the incoming 2023 Congress Chair Dr. Peter D. Higgins.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Rashid N. Lui, MD
Immune checkpoint inhibitors have evolved the treatment landscape for cancer, but we need to consider the GI side effects. To do so, Dr. Peter Buch is joined by Dr. Rashid N. Lui to assess the GI impacts of ICIs and how to manage them.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michael L. Weinstein, MD
As clinicians, providing the best quality of care is paramount. But when it comes to procedure-intensive specialties, medical malpractice is a notable concern. So what do we need to know about the common malpractice claims in the GI field, and how can we mitigate the risk of those claims? To find out, Dr. Peter Buch is joined by Dr. Michael Weinstein, President and CEO of Capital Digestive Care.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Alexander Perelman, D.O.
Proton pump inhibitors (PPIs) are among the most frequently prescribed medications in the world, but in many instances, they may be unnecessary. So how might this impact our patients’ health, and how can we identify those patients who should be prescribed PPIs? Dr. Peter Buch is joined by Dr. Alexander Perelman to talk about the overuse of PPIs.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Hetal A. Karsan, MD, FACG, FAASLD, FASGE, FACP
Primary biliary cholangitis, which was formerly known as primary biliary cirrhosis, is a chronic disease that progresses over time. Fortunately, much progress has been made in that many patients are being diagnosed and treated much earlier than before. But what exactly has changed when it comes to our detection and treatment of this disease? Dr. Peter Buch is joined by Dr. Hetal Karsan, Adjunct Professor of Medicine in the Division of Digestive Diseases at Emory University School of Medicine, to discuss key updates in primary biliary cholangitis care.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Lea Ann Chen, MD
As clinicians, we know that adherence to treatment regimens is associated with improved outcomes in our patients with inflammatory bowel disease (IBD). However, many factors can contribute to a patient's nonadherence, and understanding what those factors are, especially in underserved patient populations, is an important category of care that we need to keep in mind. Tune in to hear Dr. Peter Buch speak with Dr. Lea Ann Chen about how we can manage IBD in underserved patient populations.
Host: Jennifer Caudle, DO
Guest: Ashish S. Patel, MD
Treating IBD in our pediatric patients can be challenging, which is why creating a strong partnership between care teams and patients’ families is key. Fortunately, that was a central focus of the 2022 Crohn's & Colitis Congress, so to catch the latest updates and strategies for improving IBD care for pediatric patients, tune in to hear Dr. Jennifer Caudle speak with Dr. Ashish Patel.
Host: Jennifer Caudle, DO
Guest: Alan C. Moss, MD
When patients with moderate ulcerative colitis fail first-line therapy, it's important to know what to do next. And speaking with your patients about their risks and preferences is key. Join us as Dr. Alan Moss shares highlights from his presentation at the 2022 Crohn's & Colitis Congress on treatment considerations for patients with moderate ulcerative colitis.
Host: Neilanjan Nandi, MD
Guest: Jean-Frederic Colombel, MD
There are over a half dozen newer and emerging classes of agents for ulcerative colitis. This abundance is great news for our patients, but it also increases the complexity of treatment. Listen in as Dr. Neil Nandi and Dr. Jean-Frederic Colombel explore the roles that these agents will play in the evolving treatment landscape.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Esteban Figueroa, MD
Exploring the ACE Index in Acute Ulcerative Colitis
Rebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, Ruairi W Lynch, Philip W Jenkinson, Charlie W Lees, Thomas A Manship, Fiona A M Jagger, William M Brindle, Mrithula Shivakumar, Jack Satsangi, Ian D R Arnott
Background: Intravenous (IV) steroids remain the first-line treatment for patients with acute ulcerative colitis (UC). However, 30% of patients do not respond to steroids, requiring second-line therapy and/or surgery. There are no existing indices that allow physicians to predict steroid nonresponse at admission. We aimed to determine if admission biochemical and endoscopic values could predict response to IV steroids.
Methods: All admissions for acute UC (ICD-10 K51) between November 1, 2011, and October 31, 2016 were identified. Case note review confirmed diagnosis; clinical, endoscopic, and laboratory data were collected. Steroid response was defined as discharge home with no further therapy for active UC. Nonresponse was defined as requirement for second-line therapy or surgery. Univariate and binary logistic regression analyses were employed to identify factors associated with steroid nonresponse.
Results: Two hundred and thirty-five acute UC admissions were identified, comprising both acute severe and acute nonsevere UC; 155 of the 235 patients (66.0%) …
Host: Neilanjan Nandi, MD
Guest: David T. Rubin, MD
The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or second-line non-responders. This creates not only new challenges, but also new opportunities for all community gastroenterologists. Dr. Neil Nandi and Dr. David Rubin walk us through a case to highlight some of these challenges.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Erick Argueta, MD
Since only 70 percent of initial eradication attempts of Helicobacter pylori are successful, it’s important for us to understand the factors that might be contributing to this startling statistic. That’s why Dr. Peter Buch speaks with Dr. Erick Argueta about why Helicobacter pylori can be difficult to eradicate and how we can best treat this infection.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Benjamin L. Cohen, MD
Inflammatory bowel disease (IBD) among the elderly is common, and when compared to IBD in younger patients, it’s characterized by a different disease course and has an increased risk of mortality. So how can we achieve better outcomes for our elderly patients? Dr. Peter Buch is joined by Dr. Benjamin Cohen, Co-Section Head and Clinical Director for Inflammatory Bowel Disease at the Cleveland Clinic, to discuss evaluation and treatment strategies for our elderly patients with IBD.
Host: Neilanjan Nandi, MD
Guest: Samir Shah, MD
From new guideline recommendations to a concert featuring the American College of Gastroenterology’s official band, a lot is being done to help raise awareness of the importance of screening for colorectal cancer. So how can you help increase screening rates in your own community? Get inspired with these creative initiatives shared by Dr. Neil Nandi and Dr. Samir Shah, President of the American College of Gastroenterology.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michelle Hughes, MD
Over the past two decades, there has been an increasing need for GI hospitalists to help provide rapid access to care. Since then, GI hospitalists have become an important part to many healthcare systems and their approach to patient care. Joining Dr. Peter Buch to discuss the benefits and challenges that come along with the GI hospitalist role is Dr. Michelle Hughes, Assistant Professor of Medicine and Medical Chief of Quality and Safety for Digestive Health at Yale New Haven Health.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Amir E. Masoud, MD
Gastroparesis affects approximately five million people in the United States alone, and there are more than 50 recognized causes. In recent years, however, it's been shown that simply accelerating gastric emptying may not improve symptoms, and the overlap of functional dyspepsia and gastroparesis has further clouded our understanding of this condition. So to help clear up some of that confusion, Dr. Peter Buch speaks with Dr. Amir Masoud about treatment strategies for gastroparesis.
Host: Neilanjan Nandi, MD
Guest: Karen Krok, MD, FAASLD
While hepatologists can help gastroenterologists manage the pulmonary manifestations that may occur in our patients with chronic liver disease, it’s still important for gastroenterologists to know what they should be on the lookout for so that patients can receive timely and appropriate treatment. Additionally, gastroenterologists need to consider the potential impacts of those pulmonary manifestations on transplant outcomes. Joining Dr. Neil Nandi to discuss those and other key considerations gastroenterologists need to know is Dr. Karen Krok from Penn State Health Milton S. Hershey Medical Center.
Host: Neilanjan Nandi, MD
Guest: Nitin K. Ahuja, MD
The symptoms of early satiety, chronic nausea, and even vomiting can be physically and emotionally challenging for the gastroparesis patient. Adding to the challenge is the fact that the journey from diagnosis to treatment is often daunting and frustrating. So to help us combat these challenges, Dr. Neil Nandi speaks with Dr. Nitin Ahuja, who walks us through the ins and outs of diagnosing and managing gastroparesis.
Host: Neilanjan Nandi, MD
Guest: Nicholas Shaheen, MD, MPH
How do we determine which of our patients with Barrett's esophagus with dysplasia are good candidates for ablation therapy, and what’s the role of the gastroenterologist in serving patients who've already received post-ablative therapy? Joining Dr. Neil Nandi to answer those and other key questions is Dr. Nicholas Shaheen, who was the primary investigator of one of the largest multicenter studies of radiofrequency ablation.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Donna Cipolla, MD
Microscopic colitis can have a variety of symptoms ranging from very mild to debilitating. Fortunately, there are several treatment options and strategies available that can help you alleviate your patient’s symptoms. Joining Dr. Peter Buch to share those options and strategies is Dr. Donna Cipolla.
Host: Neilanjan Nandi, MD
Guest: Monica Schwartzman, MD, MS
It's currently estimated that 50 percent of IBD patients experience some form of joint stiffness, otherwise known as arthralgia. With so many patients being affected, how can you determine if it’s inflammatory or noninflammatory arthralgia and treat it appropriately? To find out, Dr. Neil Nandi speaks with Dr. Monica Schwartzman, assistant attending physician at the Hospital for Special Surgery and Clinical Instructor of Medicine at Weill Cornell Medical College. Together, they’ll discuss the screening tools gastroenterologists can use to differentiate the types of arthralgia in their patients as well as key management approaches.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Jonathan Leighton, MD
If you suspect your patient might have small bowel bleeding despite a massive workup, what evaluation tools are at your disposal to help you find out for sure? Tune in to hear Dr. Peter Buch explore the available tools—and their inherent challenges to be aware of—with Dr. Jonathan Leighton, one of the nation’s leading experts on small bowel bleeding.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Naga Chalasani, MD
Drug-induced liver injury (DILI) continues to be one of the leading causes of acute liver failure, and its prevalence is only increasing. That’s why Dr. Peter Buch speaks with leading expert Dr. Naga Chalasani, who talks about everything we need to know about DILI—from its phenotypes to common symptoms to look for in patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Manish Thapar, MD, AGAF, FAASLD, FACG
Acute hepatic porphyria (AHP) is a rare genetic condition characterized by severe, diffuse abdominal pain and a broad range of seemingly unrelated symptoms. AHP presents differently in each patient, with symptoms that mirror those of more common conditions, making it difficult to diagnose. Although AHP can be misleading, it can be easy to detect once you know what to look for. Joining Dr. Charles Turck to discuss AHP signs and symptoms and when a doctor should consider AHP in a patient is porphyria expert Dr. Manish Thapar, gastroenterologist and associate professor of medicine in Philadelphia.
©2021 Alnylam Pharmaceuticals, Inc. All Rights Reserved. AS1-USA-01069
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Caren Heller, MD, MBA
For patients living with IBD, paying special attention to their nutrition is paramount. So which is more effective for IBD patients with mild-to-moderate symptoms: a Mediterranean style diet or the Special Carbohydrate diet? That’s what the Diets to Induce Remission in Crohn's Disease (DINE-CD) study sought to find out, and now the results are in. Join Dr. Peter Buch as he explores the study's key findings with Dr. Caren Heller, Chief Scientific Officer at the Crohn's and Colitis Foundation.
Host: Neilanjan Nandi, MD, FACP
Guest: Sergio Schwartzman, MD
Inflammatory bowel disease (IBD) has long been associated with the development of arthritis, which can be detected in up to 30 percent of IBD patients. So how can gastroenterologists and rheumatologists work together to detect and manage IBD-associated arthritis? To find out, Dr. Neil Nandi speaks with rheumatologist Dr. Sergio Schwartzman about IBD-associated arthritis.
Host: Neilanjan Nandi, MD
Guest: Susan Kais, MD
Many IBD clinicians and patients talk about diet, but not many conversations happen about fitness. Based on the latest research, exercise may be one therapeutic tool in our kit that remains unexploited. That’s why IBD specialist Dr. Susan Kais joins Dr. Neil Nandi to walk us through key findings and how we can prescribe fitness for our IBD patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
Screening for colorectal cancer is unique because there are several screening options available. So how can we balance the latest ACG Clinical Guidelines with patient preferences, cultural context, and insurance coverage to find the best screening option for our patients? Joining Dr. Peter Buch to discuss the updated recommendations is Dr. Aasma Shaukat, lead author of the 2021 ACG Clinical Guidelines for colorectal cancer screening.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Neilanjan Nandi, MD
Guest: Gary Falk, MD
Once we’ve diagnosed a patient with Barrett’s esophagus, strict surveillance is necessary to help prevent the development esophageal cancer. But what do surveillance strategies look like according to the latest guidelines? Joining Dr. Neil Nandi to share how we can best maximize surveillance guidelines for Barrett's esophagus and apply some of the evolving technologies that are helping us do just that is Dr. Gary Falk, Director of the Esophagology and Swallowing Center at the University of Pennsylvania.
Host: Neilanjan Nandi, MD
Guest: Jason Schairer, MD
How can we make the differentiation between pouchitis and cuffitis to provide the best possible care? And once we accurately identify and treat pouchitis, how can we manage surgical complications that may arise? Tune in to hear Dr. Jason Schairer from the Henry Ford Health System in the Division of Gastroenterology and Hepatology discuss these FAQs with Dr. Neil Nandi.
Host: Ricardo Franco, MD
Guest: David L. Wyles, MD
The COVID-19 pandemic has taken a disproportional toll on already vulnerable persons, yet substance use, psychosocial comorbidities, and preexisting disparities in access to care may translate to an even greater adverse impact among persons with chronic HCV. This educational activity offers up-to-date information on the impact of COVID-19 on the normal and HCV-infected liver, practical strategies for optimizing telehealth-delivered HCV care, and other recommendations for engaging vulnerable populations in HCV care during times of reduced service capacity.
Host: Jennifer Caudle, DO
Guest: Stephen Hanauer, MD
Even though biosimilars serve as a much-needed treatment option for patients in several fields of medicine, gastroenterologists have been reluctant to adopt them. Joining Dr. Jennifer Caudle to explore why this might be and the evolving role of biosimilars in anti-inflammatory care for GI patients is Dr. Stephen Hanauer, Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
USA-CBU-81030
Host: Neilanjan Nandi, MD
Guest: James D. Lewis, MD, MSCE
An ongoing question for clinicians and patients alike is how diet can impact IBD treatment and management. Here to discuss this topic with Dr. Neil Nandi is Dr. James Lewis of the University of Pennsylvania IBD Center. Dr. Lewis recently conducted a clinical randomized trial that compared the impact of two diets on patients with mild-to-moderate Crohn’s disease symptoms, and now, Drs. Nandi and Lewis are diving into this study, the reasoning behind it, and its outcomes.
Guest: Cheryl Pirozzi, MD, MS
Guest: Charlie Strange, MD
Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.
Host: Neilanjan Nandi, MD
Guest: Jordan E. Axelrad, MD, MPH
Many IBD patients and clinicians shy away from the topic of sexual health—and understandably so. Talking about sex in the clinic sadly remains a taboo, and there’s not many research studies exploring IBD and sexual health to use for guidance. But sexuality and intimacy are vital matters to discuss with our patients, which is why Dr. Jordan Axelrad joins Dr. Neil Nandi to share how we can facilitate an open and honest conversation with patients about their sexual health.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Amanda Ayers, MD, FACS
Many patients undergo surgery to help manage their inflammatory bowel disease (IBD), but many questions still surround the surgical management of IBD. When should a patient receive surgery? How do we know which procedure is best? And what do we need to keep in mind before, during, and after a patient's surgery? Joining Dr. Peter Buch to help address those and other questions is colorectal surgeon Dr. Amanda Ayers.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Corey A. Siegel, MD, MS
Predicting which patients with IBD will develop complications allows for much better medication choices. But how do we go about predicting that risk? Joining Dr. Peter Buch to tackle this topic is Dr. Corey Siegel, Section Chief of Gastroenterology and Hepatology at Dartmouth-Hitchcock Medical Center.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Christopher J. DiMaio, MD
The approach to managing pancreatic necrosis has evolved over the past several years. To learn more, Dr. Peter Buch speaks with Dr. Christopher J. DiMaio, who’s one of the lead authors of the clinical practice update from the American Gastroenterological Association focusing on the management of pancreatic necrosis.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Randolph Steinhagen, MD
Despite significant advances in Crohn’s disease therapy, sometimes patients have no other option but surgery. So to learn more about surgery for Crohn’s disease, Dr. Peter Buch speaks with Dr. Randolph Steinhagen, Chief of the Division of Colorectal Surgery and the Director for the Colon and Rectal Fellowship Program at Mount Sinai.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michael Camilleri, MD
Many of our patients suffer from bile acid diarrhea. In fact, it’s estimated that about a third of the patients with functional diarrhea or irritable bowel syndrome with diarrhea actually have bile acid malabsorption or bile acid diarrhea, and one in every five adolescents with chronic diarrhea have evidence of bile acid diarrhea based on very simple blood tests. But despite its prevalence, bile acid diarrhea is often difficult to diagnose, which is why Dr. Peter Buch and Dr. Michael Camilleri from the Mayo Clinic come together to discuss key diagnostic and treatment strategies for bile acid diarrhea.
Host: Neilanjan Nandi, MD
Guest: Kristle Lynch, MD
There are many questions and considerations that arise when managing patients with eosinophilic esophagitis, which is exactly what the 2020 AGA guidelines seek to address. Joining Dr. Neil Nandi to walk us through those guidelines and how we can apply them to the care of our patients with eosinophilic esophagitis is Dr. Kristle Lynch, Associate Professor Clinical Medicine Division of Gastroenterology and Hepatology at the Perelman School of Medicine at the University of Pennsylvania.
Host: Joel Wedd MD, MPH
Not only is hepatocellular carcinoma (HCC) the most common primary liver cancer in adults, but it’s also the fastest-growing cause of cancer-related deaths in the US. That’s why Dr. Joel Wedd, Associate Professor of Medicine at the Virginia Commonwealth University and Medical Director of Liver Transplant at the Hume-Lee Transplant Center, is here to discuss the pathogenesis of hepatocellular carcinoma, risk factors, the importance of early-stage detection, and more.
Host: Eric Verdin, MD
Here to talk about some of the cellular changes associated with aging, how these changes manifest clinically as we age, and emerging nutritional interventions to target these changes is Dr. Eric Verdin, the President and Chief Executive Officer of the Buck Institute for Research on Aging.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Jeffrey Hyams, MD
Many studies focus on the impact of Crohn’s disease and ulcerative colitis in adult patients, but what about our youngest patients? To learn more about how we can treat our pediatric patients with Crohn’s disease and ulcerative colitis, Dr. Peter Buch speaks with Dr. Jeffrey Hyams, one of the world’s leading experts in pediatric inflammatory bowel disease.
Guest: Jordan E. Axelrad, MD, MPH
Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)
Mark T Osterman, Frank I Scott, Franz F Fogt, Erin D Gilroy, Susan Parrott, Joseph Galanko, Raymond Cross, Alan Moss, Hans H Herfarth, Peter D R Higgins
Abstract
Objective: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse.
Design: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley …
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Hamita Sachar, MD
Over the years, there has been an immense focus on defining what really constitutes a high-quality endoscopy, but many questions still remain regarding what that actually looks like in practice and how we can ensure quality in endoscopy units. That’s why Director of Ambulatory Services and Digestive Disease at Yale School of Medicine Dr. Hamita Sachar joins Dr. Peter Buch to help address some of those questions.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Russell D. Cohen, MD, FACG, AGAF
Are patients with inflammatory bowel disease (IBD) at increased risk for COVID-19 infection? And what should we recommend for an IBD patient in remission who tests positive for COVID-19 versus a patient with active disease? These are just some of the questions that have arisen since the onset of the COVID-19 pandemic, and the questions Dr. Peter Buch explores with Dr. Russell Cohen, Director of Inflammatory Bowel Disease Center and Co-Director of the Advanced IBD Fellowship Program at the University of Chicago School of Medicine.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Mark Pimentel, MD
Small intestinal bacterial overgrowth (SIBO) can be a challenging condition to navigate due to the several controversies surrounding its testing and treatment. Joining Dr. Peter Buch to discuss these complex issues and controversies is Dr. Mark Pimentel, Director of the Medically Associated Science and Technology Program at Cedars Sinai in Los Angeles and author of the “ACG Clinical Guideline Small Intestinal Bacterial Overgrowth” article published in the American Journal of Gastroenterology in 2020.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Asher A. Kornbluth, MD
Since the onset of the COVID-19 pandemic, many questions have arisen regarding the care of our patients with IBD. Are they at increased risk of COVID-19? How should we treat a patient with IBD who has active COVID-19? Should they get vaccinated, and if so, when? These are all questions Dr. Peter Buch addresses with Dr. Asher Kornbluth, Clinical Professor of Medicine and Gastroenterology at Mount Sinai School of Medicine in New York, to help us optimize our approach to care amid the COVID-19 pandemic.
Host: Neilanjan Nandi, MD
Guest: Kate Scarlata, MPH, RDN
Many patients tailor their diets to their gastrointestinal disorders, such as IBS, and adopt a low FODMAP regimen. What skills do we need to help screen patients for FODMAP sensitivities and identify foods they should avoid? Dr. Neil Nandi will be discussing these skills with Kate Scarlata, a registered dietitian, and a New York Times best-selling author.
Host: Neilanjan Nandi, MD
Guest: Aline Charabaty, MD
Many of us use social media to stay connected with family and friends. But have you ever considered using social media to communicate with other clinicians and even earn CME credit? Clinical Director of Gastroenterology and Director of the Inflammatory Bowel Disease Center at Sibley Memorial Hospital Dr. Aline Charabaty saw that opportunity and used it to create Monday Night IBD, and now Dr. Charabaty is here to talk about that program and the benefits of social media for clinicians with Dr. Neil Nandi.
Host: Daniel Catenacci, MD
Guest: Yelena Janjigian, MD
Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.
Host: Jennifer Caudle, DO
Guest: Aryeh Shander, MD, FCCM, FCCP
Bleeding is the most common complication of anticoagulant use. And to better care for patients either experiencing acute bleeding or urgently needing surgery, it's critical that clinicians thoroughly understand how to assess, treat, and reverse anticoagulation. Dr. Jennifer Caudle sits down with Dr. Aryeh Shander to discuss some of the different considerations we should take into account when selecting a warfarin reversal option.
Please read full Prescribing Information for Kcentra®.
KCT-0033-APR21
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
Guest: Johannah Ruddy, MEd
Gender bias and trauma are prevalent issues that have far-reaching impacts on our GI patients’ health and even our diagnostic and treatment approaches. To learn more about how gender bias and trauma impact patients and clinicians alike, Dr. Peter Buch is joined by Dr. Douglas Drossman and patient advocate Ms. Johanna Ruddy from the Rome Foundation.
Host: Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Guest: Joseph Lim, MD
Guest: Danny Chu, MD
Guest: Jian Q. Zhang, DNP, MS, FNP-BC, NEA-BC, FAAN
Experts in chronic hepatitis B within Asian communities discuss prevention, screening and management options to reduce the number of new cases and the risk of progression to cirrhosis, hepatic failure, and hepatocellular carcinoma. Experts also will consider the integration of Western and Eastern Medicine approaches to treatment and how cultural perceptions and community stigmatization of persons of Asian descent with chronic HBV infection can create barriers to diagnosis and care.
Host: Neilanjan Nandi, MD
Guest: Austin Chiang, MD, MPH
The field of endoscopic bariatric weight loss has developed over the years, but there’s a lot we still don’t know. Dr. Neil Nandi is here today with Dr. Austin Chiang, Director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, to provide some insight on advanced endoscopy for bariatric weight loss.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Arlene Wright, DNP, APRN, FNP-BC, FNAP
Thanks to recent research and advancements, our understanding and treatment of gastroesophageal reflux disease (GERD) has greatly evolved over the years. So what do we now know about diagnosing and treating this common GI disorder? Find out with Dr. Peter Buch and Dr. Arlene Wright, President of the Florida Nurse Practitioner Network and Executive Vice President of the Nurse Practitioners of Lee County, Florida.
Host: Neilanjan Nandi, MD
Guest: Freddy Caldera, DO
Many IBD patients have received their COVID-19 vaccine, but many others still have reservations due to the abundance of myths and misconceptions surrounding the COVID-19 vaccines. That’s why Dr. Neil Nandi welcomes Dr. Freddy Caldera to discuss these common fears and challenges as well as some of the very best answers to address the concerns of our immunosuppressed IBD patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Rajeev Attam, MD
Pancreatic cysts may be detected in up to 50 percent of patients undergoing intraabdominal MR imaging. But not all of them are malignant, so how can we determine which patients need further testing, monitoring, and perhaps even surgery? Joining Dr. Peter Buch to answer that and other questions is gastroenterologist Dr. Rajeev Attam.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Colin T. Swales, MD
Should sobriety and drug abstinence be required for hepatitis C therapy? Dr. Peter Buch dives into this dilemma with Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital, as he walks us through both sides of this controversial issue.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Adam Olsen, MS, PA-C
Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
Guest: Johannah Ruddy, MEd
Patients suffering from disorders of the gut-brain interaction are often subjected to stigma. But what can we do to help challenge these stigmas? Here today is Dr. Peter Buch who will be joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to talk about the impact of stigma in DGBI.
Guest: Xiaohong Wang, MD, PhD
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study
Walter Reinisch, Remo Panaccione, Peter Bossuyt, Filip Baert, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, William J Sandborn, Stefan Schreiber, Sofie Berg, Qian Zhou, Kristina Kligys, Ezequiel Neimark, Ahmed A Suleiman, Geert D'Haens, Jean-Frederic Colombel
Background: CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points.
Methods: The proportion of patients achieving CD Endoscopic Index of Severity (CDEIS) <4 and no deep ulcers 48 weeks after randomization was evaluated according to CRP <5 mg/L or ≥5 mg/L and FC <250 μg/g or ≥250 μg/g. Subgroup analyses were performed according to disease location, and sensitivity analyses were conducted in patients with elevated CRP and/or FC at baseline. The association between endoscopic end points and biomarker cutoffs was performed using …
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Andres Nieto, MD
The COVID-19 pandemic has demonstrated the effectiveness of telemedicine, but will this approach still be utilized after the pandemic ends? Dr. Peter Buch is joined by Dr. Andres Nieto, Assistant Professor at Frank H. Netter MD School of Medicine, to discuss the role of telemedicine and its future
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Scott Gabbard, MD
Dyspepsia affects a large number of Americans. But what exactly is dyspepsia? And how can we distinguish dyspepsia from other diseases? Joining Dr. Peter Buch to answer those and other questions is Dr. Scott Gabbard, who’s the section head of the Neurogastroenterology and Motility Center at the Cleveland Clinic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: John Allen, MD
The world of healthcare continues to drastically change over the years. But what do you need to know about the variety of employment models available for gastroenterologists today? Dr. Peter Buch is joined by Dr. John Allen, Clinical Professor of Medicine at the University of Michigan School of Medicine, to discuss recent changes in practice models.
Guest: Monica L. Baskin, PhD
Guest: Josep M. Llovet, MD, PhD
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC.
Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis.
In this activity, the expert faculty will review health disparities, inequities, and …
Host: Neilanjan Nandi, MD
Guest: Sunanda Kane, MD, MSPH, AGAF
Follow Dr. Sunanda Kane and Dr. Neil Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenario of a patient with IBD. Would you make the same decisions?
Host: Neilanjan Nandi, MD
Guest: Russell D. Cohen, MD, FACG, AGAF
New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and Dr. Neil Nandi as they explore the role of these targets in addressing the various unique IBD phenotypes that lead to loss of response over time, as well as provide practical insights into selecting the right therapy at the right time for your patient.
Host: Neilanjan Nandi, MD
Guest: Folasade P. May, MD, PhD, MPhil
Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalities in access to care and screening for patients with colorectal cancer.
Host: Neilanjan Nandi, MD
Guest: Gary R. Lichtenstein, MD, FACG, FACP, AGAF
Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation, and that do not possess broad immunosuppressive properties. Join Dr. Gary Lichtenstein and Dr. Neil Nandi as they break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Nicole Hanley-Williams, MD
The management of motility disorders like achalasia and gastroparesis can be very complex for both patients and clinicians alike. Fortunately, there have been several advancements in the evaluation and treatment of these disorders. Joining Dr. Peter Buch to walk us through what those developments are and how they can help improve our patients’ quality of life is Dr. Nicole Hanley-Williams, who specializes in motility and functional disorders at Beth Israel Lahey Health.
Host: Neilanjan Nandi, MD
Guest: Miguel Regueiro, MD, AGAF
Treat-to-target is the current standard for the management of IBD, and as such it is imperative to understand what those targets are, what strategies will help you achieve them, and the importance of integrating a patient-focused therapeutic plan. Join Dr. Miguel Regueiro and Dr. Neil Nandi as they explore practical approaches to defining therapeutic success and provide listeners with solutions and recommendations to ultimately improve long-term IBD patient outcomes.
To view and download the Crohn's and Colitis Foundation's appeal letters referenced in this program, click here!
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Jeffrey Basile, MD
Now that we have therapies like vedolizumab and ustekinumab, many are wondering if there’s still a role for anti-TNFs in the treatment of IBD. Here to share his perspective and how he uses the multitude of available treatment options to his advantage is Dr. Jeffrey Basile, a gastroenterologist from Charleston GI.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Paul Feuerstadt MD, FACG, AGAF
Clostridium difficile impacts many patients around the United States. How can we better diagnose and treat this infection? Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor of Medicine at Yale New Haven Hospital the discuss the importance of managing Clostridium difficile.
Host: Neilanjan Nandi, MD
Guest: Brian E. Lacy, MD, PhD
What do we need to know about choosing the right medication for our patients with IBS? Stay tuned as Dr. Neil Nandi talks with Dr. Brain Lacy, a gastroenterologist at the Mayo Clinic, Jacksonville, and the co-editor-in-chief of the American Journal of Gastroenterology, on these pharmacologic therapies.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Frank Scott
Dr. Charles Turck is joined by Dr. Frank Scott from the University of Colorado School of Medicine to share some highlights from his session, “Challenges and New Approaches to Managing IBD in the COVID-19 Era,” at Crohn’s & Colitis Congress 2021.
Host: Neilanjan Nandi, MD
Guest: Tiffany H. Taft, PsyD
Avoidant Restrictive Food Intake Disorder, AFRID, is a newly introduced eating disorder at the forefront of GI care. Stay tuned to hear Dr. Neil Nandi discuss the impact of ARFID on GI health with Dr. Tiffany Taft, the Director of Psychogastroenterology Research in the Division of Gastroenterology and Hepatology at Northwestern University.
Host: Neilanjan Nandi, MD
Guest: Maria T. Abreu, MD
Environmental factors can affect many different aspects of a patient’s heath, but how do these factors play a role in developing inflammatory bowel disorders, or IBD? Tune in to hear Dr. Neil Nandi and Dr. Maria Abreu, the director of the Crohn’s and Colitis Center at the University of Miami, discuss the role of environmental factors in patients at risk of developing IBD.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Joseph C. Anderson, MD
Colon cancer rates for patients younger than 50 have increased at an alarming rate. How can we help screen our younger individuals for colon cancer? Tune in to hear Dr. Peter Buch speak with Dr. Joseph Anderson, Associate Professor of Medicine at Dartmouth, to discuss the transitions occurring in colon cancer screening.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
Guest: Johannah Ruddy, MEd
A strong doctor-physician partnership is a critical component of patient care. Here today is Dr. Peter Buch who will be joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to discuss how to build this foundation and maintain the relationship.
Host: Peter Buch, MD, FACG, AGAF, FACP
While diverticulitis is a common disease, what can be done to help better understand this infection? Here today is our GI Insights host, Dr. Peter Buch, to discuss complications and approaches to managing and treating diverticulitis.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Devika Umashanker, MD
Obesity is a worldwide phenomenon and linked to morbidity and mortality. How can we help our obese patients along their weight loss journey to ensure long-term success? Dr. Peter Buch is joined by Dr. Devika Umashanker, Obesity Medicine Director of the Department of Bariatric Surgery at Hartford HealthCare Medical Group, to assess strategies for helping your patients see positive long-term weight loss outcomes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Marla C Dubinsky, MD
Considering available therapeutics, how can we make the most of the drugs at our disposal for patients with inflammatory bowel disorders, or IBD? Ahead of her presentation at the 2021 Crohn's & Colitis Congress, Dr. Marla Dubinsky of Mount Sinai Kravis Children's Hospital discusses how current treatments can be used to not only ensure survival but also improve quality of life.
Host: Neilanjan Nandi, MD, FACP
The COVID-19 pandemic has presented a unique set of challenges for healthcare professionals. What are some of the biggest threats to our GI patients, and how should we help them stay safe? Here today is our GI Insights host, Dr. Neil Nandi, to shed some light on his experiences while caring for patients during the pandemic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Richard Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD
Non-invasive assessments of liver fibrosis can be subcategorized into many different tests. What do we need to know about these increasingly popular assessments? Dr. Peter Buch is joined by Dr. Richard Sterling, professor of medicine at Virginia Commonwealth University to discuss when it is appropriate to use each of these assessments for patients with liver fibrosis.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kyle Staller, MD, MPH
Misconceptions around chronic idiopathic constipation can make it challenging to diagnose and treat. What do we need to know to help our patients manage this condition? Dr. Peter Buch is joined by Dr. Kyle Staller, assistant professor of medicine at the Harvard Medical School to discuss these myths and misconceptions about constipation.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Irritable bowel syndrome, or IBS, is a common disorder that can be challenging to treat. What is the best therapeutic approach to treating this condition? Dr. Peter Buch is joined by Wendy Wright, an adult and family nurse practitioner from New Hampshire, to discuss how to test and treat patients with IBS from a primary care perspective.
Host: Neilanjan Nandi, MD
Guest: Brennan Spiegel, MD, MSHS
Virtual reality has shown the ability to decrease pain, reduce opioid dependence, and boost mental health. How is this digital therapeutic changing the treatment landscape for gastroenterology? Dr. Neil Nandi is joined by Dr. Brennan Spiegel, Director of the Cedars-Sinai CORE program, on his innovative research about the positive impact of virtual reality in gastroenterology.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: John R. Saltzman, MD
Gastrointestinal bleeding, or GI bleeding, is a serious but common condition, and upper GI bleeding requires an individualized approach. How can we better detect and manage this condition? Dr. Peter Buch will be discussing the importance of managing upper GI bleeding with Dr. John Saltzman, Director of Endoscopy at the Brigham and Women’s Hospital.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
Effective communication is essential to improving the patient-provider relationship. What is the best approach a physician can take when speaking to patients with IBS? Dr. Peter Buch will discuss valuable communication strategies with Dr. Douglas Drossman, president of the Rome Foundation.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Lawrence Schiller, MD, FAP, FACG
Patients with chronic diarrhea are often misdiagnosed with irritable bowel syndrome with diarrhea, or IBS-D. How can we better assess these patients to prevent misdiagnosis? Joining Dr. Peter Buch to discuss diagnostic tools and testing strategies is Dr. Lawrence Schiller, Program Director of the Gastroenterology Fellowship at Baylor University Medical Center.
Guest: James Lindsay PhD, BM BCh, FRCP
Nutrition plays an important role in inflammatory bowel disease, but it’s important to instill in patients the understanding that even though a healthy diet can help reduce symptoms, it doesn’t mean that the disease itself has improved. Here to share how he talks about nutrition with his patients and other key management strategies like the low FODMAP diet is Dr. James Lindsay, Professor of Inflammatory Bowel Disease at Barts Health in London.
Published August 27, 2020
Host: Stacy Kahn, MD
Inflammatory bowel disease in pediatric patients is not as uncommon as you may think. Dr. Stacy Kahn, Assistant Professor of Pediatrics at Boston Children’s Hospital, shares her experience with healthy diet plans, preparing families for transition, and more.
Published August 7, 2020
Host: Ivy Ka Man Law, PhD
A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice
Marina Liso, Stefania De Santis, Giulio Verna, Manuela Dicarlo, Maria Calasso, Angelo Santino, Isabella Gigante, Rajaraman Eri, Sathuwarman Raveenthiraraj, Anastasia Sobolewski, Valeria Palmitessa, Antonio Lippolis, Mauro Mastronardi, Raffaele Armentano, Grazia Serino, Maria De Angelis, Marcello Chieppa
Background: Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC), is a multifactorial disorder characterized by chronic inflammation and altered gut barrier function. Dysbiosis, a condition defined by dysregulation of the gut microbiome, has been reported in patients with IBD and in experimental models of colitis. Although several factors have been implicated in directly affecting gut microbial composition, the genetic determinants impacting intestinal dysbiosis in IBD remain relatively unknown.
Methods: We compared the microbiome of normal, uninflamed wild-type (WT) mice with that of a murine model of UC (ie, Winnie strain). Winnie mice …
Host: Abdullah Abdussalam, MD
Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s
Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD
Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX.
Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.
Guest: Anita Afzali MD, MPH, FACG, AGAF
The management of IBD remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Anita Afzali presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
Guest: David P. Hudesman, MD
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Hudesman presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
Host: Matt Birnholz, MD
Guest: Emeran Mayer, MD, PhD
There’s no organ in the body that has such close connections with the brain as the gut, which can often result in pain for many of our patients with IBD. Listen in as Dr. Emeran Mayer joins Dr. Matt Birnholz to explain this mind-gut connection, why patients with IBD experience pain, and how providers can manage patients who experience pain when inflammation is and isn't present.
Host: Matt Birnholz, MD
Guest: Uma Mahadevan, MD
Whether you’re a seasoned veteran in the field or a newly practicing clinician, successful time management and work-life balance can be difficult to achieve. Tune in for key tips and tricks from Dr. Uma Mahadevan.
Host: Matt Birnholz, MD
Guest: Tiffany H. Taft, PsyD
Since the brain-gut connection directly impacts the biopsychosocial well-being of IBD patients, Dr. Matt Birnholz sits down with Dr. Tiffany Taft, Director of Psychogastroenterology Research in the Division of Gastroenterology and Hepatology at Northwestern University, to discuss how integrating psychogastroenterology principles and techniques into your practice can help alleviate the burden of IBD on your patients.
Host: Matt Birnholz, MD
Guest: Jeremy Adler, MD
To catch us up to spend on the unique care needs of our pediatric patients with IBD, Dr. Matt Birnholz spoke with Dr. Jeremy Adler, Head of the Pediatric IBD Program at the University of Michigan, at the third annual Crohn’s & Colitis Congress in Austin, Texas.
Host: Matt Birnholz, MD
Guest: Corey A. Siegel, MD, MS
At the third annual Crohn’s & Colitis Congress in Austin, Texas, Co-Director of the IBD Program and Section Chief of Gastroenterology and Hepatology at the Dartmouth-Hitchcock Medical Center Dr. Corey Siegel sat down with Dr. Matt Birnholz to share his approach to presenting risk data to his IBD patients.
Host: Matt Birnholz, MD
Guest: Frank Scott, MD
Disease and drug monitoring can help us improve our approach to managing our patients’ IBD, but when’s the right time to perform that practice and how do we go about it? Joining Dr. Matt Birnholz at the third annual Crohn’s & Colitis Congress in Austin, Texas to answer those questions and more was Dr. Frank Scott, Assistant Professor of Medicine from the Crohn’s & Colitis Center at the University of Colorado.
Host: Jennifer Caudle, DO
Guest: Neilanjan Nandi, MD
Join Dr. Neilanjan Nandi as he discusses his experiences with patients presenting with GI issues, key symptoms to be on the lookout for, and how primary care clinicians and gastroenterologists can work together with their IBD patients to provide optimal care.
Host: Jenn Simmons, MD
Guest: Jill K. Gaidos, MD
The evolution of therapies for inflammatory bowel disease (IBD) has been nothing short of remarkable, which means it’s time that we take stock of the latest treatment targets, disease mechanism updates, drug pipeline developments, and patient safety considerations. And here to help us do just that is Dr. Jill Gaidos, Associate Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University.
Guest: Anish Patel, DO, FACG
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
Chao Chen, PhD, Abraham G Hartzema, PhD, Hong Xiao, PhD, Yu-Jung Wei, PhD, Naueen Chaudhry, MD, Ofor Ewelukwa, MD, Sarah C Glover, DO, Ellen M Zimmermann, MD
BACKGROUND AND AIMS:
Medication persistence, defined as the time from drug initiation to discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit and safety. This study seeks to compare the persistence of biologic drugs among patients with inflammatory bowel disease (IBD).
METHODS:
Patients with newly diagnosed IBD were included in a retrospective study using Truven MarketScan database. Treatment persistence and switching was compared among biologic medications including infliximab, adalimumab, certolizumab, golimumab, and vedolizumab. Predictors for discontinuation and switching were evaluated using time-dependent proportional hazard regression.
RESULTS:
In total, 5612 patients with Crohn's disease (CD) and 3533 patients with ulcerative colitis (UC) were included in this analysis. Less than half of the patients continued using their initial biologic treatment after 1 year (48.48% in CD cohort; 44.78% …
Guest: Robin Dalal, MD
Improving the Quality of Inpatient Ulcerative Colitis Management: Promoting Evidence-Based Practice and Reducing Care Variation With an Inpatient Protocol
Sara M Lewin, MD, Ryan A McConnell, MD, Roshan Patel, MD, Suzanne R Sharpton, MD, MAS, Fernando Velayos, MD, MPH, Uma Mahadevan, MD
BACKGROUND:
Hospitalization for ulcerative colitis is a high-risk period associated with increased risk of Clostridium difficile infection, thromboembolism, and opiate use. The study aim was to develop and implement a quality-improvement intervention for inpatient ulcerative colitis management that standardizes gastroenterology consultant recommendations and improves delivery of evidence-based care.
METHODS:
All adult patients hospitalized for ulcerative colitis between July 1, 2014, and December 31, 2017, who received intravenous corticosteroids were included. On July 1, 2016, the UCSF Inpatient Ulcerative Colitis Protocol was implemented, featuring standardized core recommendations and a daily checklist for gastroenterology consultant notes, a bundled IBD electronic order set, and an opiate awareness campaign. The composite primary outcome was adherence to all 3 evidence-based care metrics: C. difficile testing performed, pharmacologic venous thromboembolism (VTE) prophylaxis ordered, and opiates avoided.
RESULTS:
Ninety-three ulcerative colitis hospitalizations occurred, including 36 preintervention and 57 …
Host: John J. Russell, MD
Guest: Nabil Wasif, MD
Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.
Short for hyperthermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the benefits and drawbacks of HIPEC.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Thomas Ullman, MD
Guest: Juli Tomaino, MD
Guest: Sarah Yim, MD
Biosimilar medications have now entered the clinical landscape of treatment protocols for several disciplines—including gastroenterology. Joining Dr. Thomas Ullman to discuss the biosimilars that are available for Crohn’s disease and ulcerative colitis and how other parts of the world are using them are Dr. Sarah Yim, Acting Director of the Office of Therapeutic Biologics & Biosimilars, and Dr. Juli Tomaino, a pediatric gastroenterologist and Lead Medical Officer at the FDA.
Host: Jennifer Caudle, DO
To gain more insights into how inflammatory bowel disease (IBD) affects our young patients, Dr. Jennifer Caudle connects with Caroline, a 12-year-old patient who was diagnosed with IBD at the age of 4, and her parents, Preston and Rachelle, about the challenges they face and the strategies and solutions available that can help children and teens like Caroline manage this condition.
Host: Alka Goyal, MD
Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children.
Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD
Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24.
Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula …
Host: Animesh Jain, MD
Guest: David P. Hudesman, MD
The number of IBD patients who find themselves with colorectal cancer has decreased over the past ten years due to better screening tools and medication. And to help continue that trend, Dr. Animesh Jain and Dr. David Hudesman discuss the unique risk factors and the importance of early screening at the second annual Crohn’s & Colitis Congress in Las Vegas.
Host: Eva M. Szigethy, MD, PhD
Guest: Megan E. Riehl, PsyD
Psychosocial disorders like anxiety and depression can be especially severe when combined with the physical symptoms of IBD. Fortunately, there are ways gastroenterologists, primary care providers, and mental health specialists can all work together to address these effects as early as possible, as Dr. Megan Riehl, Clinical Assistant Professor of Medicine and Clinical Psychologist at the University of Michigan, explains.
Host: Lu Ann Cahn
Guest: James D. Lewis, MD, MSCE
Whether they’re not getting enough calories or not eating a balanced diet due to disease restrictions, patients with IBD often have difficulty maintaining a healthy diet. So how can you help them navigate these diet and nutrition challenges?
Filmed live at the 2018 Crohn's and Colitis Evening of Hope, Dr. James Lewis from the University of Pennsylvania discusses strategies you can implement in your practice.
Host: Jennifer Caudle, DO
Guest: Fabrizio Michelassi, MD
As a gastrointestinal surgeon and Chairman of Surgery at Weill Cornell, Dr. Fabrizio Michelassi has witnessed the possible complications that can stem from Crohn's disease. He joins Dr. Jennifer Caudle to provide his perspective on new surgical approaches to treat strictures and fibrostenotic complications.
Guest: Shail Govani, MD, MSc
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.
Saartje Van de Vondel, MD, Filip Baert, MD, PhD, Christine Reenaers, MD, PhD, Stijn Vanden Branden, MD, Leila Amininejad, MD, Pieter Dewint, MD, PhD, Wouter Van Moerkercke, MD, Jean-François Rahier, MD, PhD, Pieter Hindryckx, MD, PhD, Peter Bossuyt, MD, Marc Ferrante, MD, PhD, and Belgian IBD Research and Development (BIRD)
BACKGROUND: Adalimumab (ADM) has been shown efficacious in ulcerative colitis (UC). In randomized controlled trials, dose escalation from 40 mg ADM every other week to 40 mg every week was required in 20%–25% of patients within 1 year. Real-life data suggest higher escalation rates. Attempts for dose de-escalation have not been studied yet. We assessed the need for, outcome of, and predictors of dose escalation and de-escalation in a large retrospective cohort of UC patients treated with ADM.
METHODS: We included 231 consecutive patients from 10 Belgian centers initiating ADM treatment for active UC before September 1, 2015 (follow-up ≥1 year in each patient). We performed detailed chart review to identify variables associated with short-term clinical benefit (based on physician global assessment and absence of rectal bleeding at week 10), success …
Host: Brian P. McDonough, MD, FAAFP
Guest: Daryl Gioffre, DC
Are our diets helping or hurting us? To examine the link between your gut and your overall health, Dr. Brian McDonough is joined by nutritionist Daryl Gioffre, who suggests that an unhealthy gut could very well be the root cause of significant health issues.
Host: Brian P. McDonough, MD, FAAFP
Guest: Tanya Altmann, MD
To investigate the concerning rise in both asthma and allergies in children, Dr. Brian McDonough is joined by Dr. Tanya Altmann, pediatrician and Editor in Chief of the American Academy of Pediatrics parenting books, to discuss why a missing component of the gut microbiome may be the potential cause and how nutrition and probiotics play a vital role in a child's growth and development.
Hear from Michael Osso, President and CEO of the Crohn’s & Colitis Foundation, as he talks about the Crohn’s & Colitis Foundation Perspectives series on ReachMD.
Host: Kathy King, RDN
Guest: Kristin Kirkpatrick, MS, RDN
Fatty liver disease affects more than thirty percent of Americans, most of whom go undiagnosed due to the typically asymptomatic early stages of the disease.
Joining Dr. Kathy King is Dr. Kristin Kirkpatrick, author of Skinny Liver and Lead Dietitian at the Cleveland Clinic Wellness Institute. From diagnosis to long-term effects, Dr. Kirkpatrick discusses how fatty liver disease has become an epidemic among the American population and the role of nutrition and lifestyle guidelines.
Host: Shira Johnson, MD
Guest: Ronald DeMatteo, MD, FACS
A Gastrointestinal Stromal Tumor (GIST) is a rare sarcoma that begins in the digestive tract or stomach, with an incident rate in the United States of approximately 4,000 to 6,000 cases per year. Since these tumors behave differently from other gastrointestinal cancers, they require a specialized treatment plan.
Host Dr. Shira Johnson chats with Ronald DeMatteo, MD, FACS, Chair of the Department of Surgery and a surgical oncologist at Penn Medicine. They discuss the diagnosis, treatment and current clinical research of GIST. Dr. DeMatteo is a world-renowned surgical expert and researcher for the rare GIST. His research breakthroughs helped develop the new standard of care for GIST.
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
Liefferinckx C1, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D. BACKGROUND: Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure.
METHODS: This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay.
RESULTS: During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12-19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12-12.09 μg/mL], P = …
From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. David Piccoli, Chief of the Division of Gastroenterology, Hepatology and Nutrition, Director of the Biesecker PediatricLiver Center, and a board-certified pediatric gastroenterologist at Children's Hospital of Philadelphia. Dr. Piccoli discusses the RISK study, supported by the Crohn’s & Colitis Foundation, and the challenges patients face with response to treatment. This pediatric study enrolled 1,800 patients at the time of their diagnosis and collected clinical, genetic, treatment and microbiome information to help to determine how the immune system works over time.
Host: Brian P. McDonough, MD, FAAFP
According to the United States Department of Agriculture, the average American consumes between 150 to 170 pounds of refined sugars every year. Excessive sugar consumption is linked to a long list of health problems, from obesity and cardiovascular disease to joint inflammation and ADHD, but most of us can’t seem to be able to stop eating sugar no matter how hard we try.
Joining Dr. Brian McDonough to address the growing threat of sugar addiction is health educator and wellness expert Dr. David Magnano.
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. BACKGROUND: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution.
METHODS: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation.
RESULTS: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). …
Host: Brian P. McDonough, MD, FAAFP
Every year, 1 in 6 Americans get sick from eating contaminated food.
USDA Food Safety expert Sarah Lichtman joins host Dr. Brian McDonough to discuss ways to safely handle food, prevent food poisoning, and minimize risk of foodborne illnesses.
Anti-TNFα Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure
Assa A1, Bronsky J, Kolho KL, Zarubova K, de Meij T, Ledder O, Sladek M, van Biervliet S, Strisciuglio C, Shamir R.
BACKGROUND: The outcome of patients with Crohn's disease who failed anti-tumor necrosis factor alpha (anti-TNFα) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNFα agent postoperatively.
METHODS: Pediatric patients with Crohn's disease who underwent intestinal resection and were treated with anti-TNFα agents postoperatively were assessed retrospectively. Patients were stratified to those with preoperative anti-TNFα pharmacodynamic failure and those with no preoperative anti-TNFα treatment.
RESULTS: A total of 53 children were included, 18 with pharmacodynamic failure and 35 controls. Median age at intestinal resection was 14.8 years with 23 (43%) girls. The median time from intestinal resection to anti-TNFα initiation was 8 months (interquartile range 4-14 months). At the time of postoperative anti-TNFα initiation, there were no differences in clinical, laboratory, and anthropometric measures between groups. Similar proportions of patients from both groups were in clinical remission on anti-TNFα treatment after 12 months and at the …
Host: Adam Ehrlich, MD, MPH
Guest: Alison Kaufman, PsyD
Our body responds to stress and anxiety in a variety of ways. For patients with IBD, the body manifests stress into various psychological issues, creating a link between IBD and mental health.
Dr. Alison Kaufman, a psychologist at Children’s Hospital of Philadelphia will discuss the common emotional reactions of IBD patients, suggesting ways for physicians to help these patients cope with their chronic disease. She is joined by Dr. Adam Ehrlich of Temple University.
Host: Rebecca Kaplan
Guest: Neil Nandi, MD
For patients with Crohn's and Colitis diseases, fecal matter transplants could be the therapy they have been waiting for. Dr. Neil Nandi, Director of the Center for Inflammatory Bowel Diseases at Drexel University College of Medicine, will discuss what fecal transplants are, outline the risks and benefits of treatment, and forecast upcoming research. He is joined by Rebecca Kaplan of the Crohn's and Colitis Foundation.
Host: Jennifer Caudle, DO
Guest: Major Kenneth Lee, IV, MD, PhD
Though a relatively rare disease, pancreatic cancer remains at the forefront of clinical discussion due to its highly aggressive nature. Dr. Major Kenneth Lee, Assistant Professor of Surgery at Penn Medicine, estimates that pancreatic cancer will become the number 2 cause of cancer death by the year 2020. This projected rise in mortality is largely due to the need for better advancement in treatment options.
Join host Dr. Jennifer Caudle and guest, Dr. Major Kenneth Lee, as they discuss major signs and symptoms associated with a pancreatic cancer diagnosis, risk factors, and treatment options.
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
Sands BE1, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K.
BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population).
METHODS: Post hoc analyses of the efficacy data for 516 TNF-naïve and 960 TNF-failure patients from the GEMINI 2 and GEMINI 3 trials were evaluated at weeks 6, 10, and 52 and included clinical remission (CD Activity Index [CDAI] score ≤150), enhanced clinical response (≥100-point decrease from baseline in CDAI score), durable clinical remission (remission at ≥80% of visits), and corticosteroid-free remission. Adverse events were summarized for the TNF-naïve and TNF-failure subgroups by treatment received.
RESULTS: Among patients who responded to vedolizumab induction at week 6, 48.9% …
Host: Jennifer Caudle, DO
Guest: Vincent Lo Re, MD, MSCE
In 2014, the CDC estimated a total of 2,194 cases of acute hepatitis across 40 states and estimates that 2.7-3.9 million people in the United States have chronic hepatitis C. Of every 100 persons affected by the disease, 75 to 85 will go on to develop chronic infection, 60 to 70 will go on to develop chronic liver disease, 5 to 20 will go on to develop cirrhosis over a period of 20–30 years, and 1 to 5 will die from the consequences of chronic infection (liver cancer or cirrhosis).
Joining our host, Dr. Jennifer Caudle, is Dr. Vincent Lo Re, Assistant Professor of Medicine and Infectious Diseases and Epidemiology at Penn Medicine. Dr. Lo Re discusses the current screening guidelines and recommendations regarding hepatitis C, long-term patient care, and the current landscape of treatment options.
Host: Matt Birnholz, MD
Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide.
Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Medicine, about new screening guidelines for detecting colorectal cancer.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough chats with physician and nutrition expert Dr. Cass Ingram, author of The Wild Turmeric Cure, about the various reported health benefits of wild turmeric as a disease-preventing spice.
Making an appropriate diagnosis of inflammatory bowel disease (IBD) requires a variety of laboratory tests, serologic studies, imaging techniques and procedures such as endoscopies, and biopsies. While many methods are widely used when IBD is suspected based on symptoms and history, some confusion persists around newer diagnostic modalities such as MRE and capsule endoscopies, as well as the utility of emerging serologic biomarker tests. Additionally, uncommon presentations of IBD such as asymptomatic ileitis further complicate diagnostic workups.
On this episode, Laura Wingate, Vice President of Education, Support, and Advocacy at the Crohn’s & Colitis Foundation, joins gastroenterologist Dr. David Binion, Co-Director at the IBD Center on Translational Research and Director of Nutrition Support Service at the University of Pittsburgh. The two discuss special diagnostic considerations for patients with IBD.
Predictors of Emergency Department Use by Persons with Inflammatory Bowel Diseases: A Population-based Study
Nugent, Zoann PhD; Singh, Harminder MD, MPH; Targownik, Laura E. MD; Strome, Trevor MS; Snider, Carolyn MD, MPH; Bernstein, Charles N. MD
Background: To describe the patterns and predictors of emergency department (ED) attendance and post-ED hospitalization by persons with inflammatory bowel disease (IBD).
Methods: We linked the University of Manitoba IBD Epidemiology Database with the Emergency Department Information System of the Winnipeg Regional Health Authority to determine the rates of presentation to the ED by persons with IBD from January 01, 2009 to March 31, 2012. Incident cases were diagnosed during the study period and all others were considered prevalent cases. Multivariate logistic regression was used to determine predictors of attendance in the ED and for hospitalization within 2 days of ED attendance.
Results: The study population included 300 incident and 3394 prevalent IBD cases, of whom 76% and 49%, respectively, attended the ED at least once during the study period. Incident cases with Crohn's disease or with a history of opioid use were more likely to attend the ED. Those …
Guest: Gil Melmed, MD
Recorded on location at the Crohn’s & Colitis Foundation's Annual Meeting in Orlando, host Laura Wingate,Vice President of Education Support and Advocacy for the Crohn's & Colitis Foundation, discusses health maintenance for IBD patients with Dr. Gil Melmed, Director of the Advanced IBD Fellowship Program and Clinical Research in the Division of Gastroenterology at Cedars-Sinai Medical Center.
Host: Lea Ann Chen, MD
Guest: Hans Herfarth, MD
Recorded on location at the Crohn’s & Colitis Foundation’s Annual Meeting in Orlando, host Dr. Lea Ann Chen, Assistant Professor of Medicine at New York University, discusses goals of therapy in IBD with Dr. Hans Herfarth, Professor of Medicine at University of North Carolina School of Medicine.
Host: Caren Heller, MD
Guest: William J. Sandborn, MD
Clinical trials, among several critical purposes, are essential for the evaluation and approval of medication options for patients living with inflammatory bowel diseases. Despite this, only 6% of clinical trials are completed on time due to unfulfilled enrollment, often stemming to communication barriers between clinicians and patients.
Host Dr. Caren Heller, Chief Scientific Officer at the Crohn's & Colitis Foundation, sits down with Dr. William Sandborn, Professor of Medicine and Adjunct Professor of Surgery at the University of California-San Diego, about the many benefits that clinical trials can provide for IBD patients.
Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study Law, Cindy C. Y. MD; Sasidharan, Saranya MD; Rodrigues, Rodrigo MD; Nguyen, Deanna D. MD; Sauk, Jenny MD; Garber, John MD; Giallourakis, Cosmas MD; Xavier, Ramnik MD, PhD; Khalili, Hamed MD, MPH; Yajnik, Vijay MD, PhD; Ananthakrishnan, Ashwin N. MD, MPH
Host: Dr. Manish Singla, Gastroenterology Division, Department of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD
Background: The management of inflammatory bowel diseases (IBDs; Crohn's disease, ulcerative colitis) is increasingly complex. Specialized care has been associated with improved ambulatory IBD outcomes.
Aims: To examine if the implementation of specialized inpatient IBD care modified short-term and long-term clinical outcomes in IBD-related hospitalizations.
Methods: This retrospective cohort study included IBD patients hospitalized between July 2013 and April 2015 at a single tertiary referral center where a specialized inpatient IBD care model was implemented in July 2014. In-hospital medical and surgical outcomes as well as postdischarge outcomes at 30 and 90 days were analyzed along with measures …
Host: Matt Birnholz, MD
The simple act of going out to eat can be a tricky proposition for people dealing with gluten intolerance or sensitivity issues. A new portable device is aiming to help people with this problem by allowing them to test food’s gluten content and help find foods that they are able to eat.
Host Dr. Matt Birnholz talks with guest Carla Borsoi, Vice President of Marketing at 6Sensor Labs, about how this device will assist people living with gluten intolerance or sensitivity issues.
Host: Brian P. McDonough, MD, FAAFP
Dr. Michael Stierstorfer, Clinical Associate Professor of Dermatology at the University of Pennsylvania School of Medicine and founder of East Penn Dermatology, has led efforts to teach clinicians about Type IV allergies as potential causes for common gastrointestinal diseases such as IBS, coining the term "allergic contact enteritis." He joins Dr. Brian McDonough to discuss intersections between dermatology and gastroenterology in the study of hypersensitivity reactions.
[Read the Article]
The U.S. Preventative Services Task Force has updated the recommendations regarding colorectal cancer screening. The Task Force strongly recommends screening average risk adults age 50 to 75 for colorectal cancer, and then making individual screening decisions for adults age 76 to 85, taking into account the patient's overall health and screening history.
Colorectal cancer is the second leading cause of cancer death in the United States, and about one-third of adults in the United States have never been screened.
[Watch more videos of The JAMA Report]
Host: Matt Birnholz, MD
Guest: Gene Kestenbaum
When children are confronted with serious chronic diseases, parents often go to extraordinary lengths to advocate on their children's behalf. In some cases, this mission expands into tireless efforts to raise awareness and fundraise for research towards a cure. Guest Gene Kestenbaum did just this when his son was diagnosed with Crohn’s Disease several years ago. His advocacy work for his child led him to become a national activist, and he served as President for the Crohn’s and Colitis Foundation.
Host Dr. Matt Birnholz sits down with Mr. Kestenbaum, who participated in the expert panel for the Villanovans in Healthcare event. They discuss his past and present involvement with Crohn's and Colitis Foundation and supporting ongoing efforts to find a cure for inflammatory bowel diseases.
Host: Brian P. McDonough, MD, FAAFP
Guest: Andrea Shin, MD
Dr. Brian McDonough welcomes Dr. Andrea Shin, practicing gastroenterologist and Assistant Research Professor of Medicine at Indiana University School of Medicine. They discuss the unique physical, emotional, and social challenges faced by people dealing with irritable bowel syndrome (IBS). They also focus on the three types of IBS (constipation, diarrhea, and constipation/diarrhea), and how to best manage each condition.
Host: Barnett Mennen, MD
Guest: Maarouf Hoteit, MD
Hepatocellular carcinoma is one of the top ten causes of cancer death in the United States, and is the most rapidly increasing cause of cancer death in men. What's more, incidence rates are on the rise. For these reasons, understanding the nuances of early liver cancer detection, and treating underlying liver diseases prior to cancer development, have been more urgently needed.
Joining Dr. Barry Mennen to discuss diagnostic, medical, and surgical priorities for managing hepatocellular carcinoma is Dr. Maarouf Hoteit, Assistant Professor of Clinical Medicine, Director of the Multidisciplinary Liver Tumor Clinic, and Program Director of the Transplant Hepatology Fellowship at the University of Pennsylvania Perelman School of Medicine.
Host: Matt Birnholz, MD
Inflammation plays a pivotal role in the development and persistence of many chronic diseases, but only recently has the human microbiome been linked as something more central to inflammatory processes than a passive reservoir. What roles do the gut, microbiome, and gut-brain axis play in chronic disease development, as well as prevention?
From the floors of the A4M Conference in Las Vegas, Dr. Matt Birnholz speaks with James LaValle, founder and CEO of Metabolic Code Enterprises, Inc and a nationally recognized clinical pharmacist, author, and board certified clinical nutritionist. The two discuss expanded understandings of the microbiome's influence on human health and disease, both in the U.S. and worldwide.
Host: Brian P. McDonough, MD, FAAFP
Respiratory complications of GERD are surprisingly common, particularly in patients experiencing silent, asymptomatic reflux for long periods of time. Yet the frequently subclinical nature of this disease progression is especially difficult to detect. How can clinicians better identify this rising issue, and are current treatment paradigms in primary care enough?
Joining Dr. Brian McDonough is Dr. Jamie Koufman, Professor of Otolaryngology at the Icahn School of Medicine at Mount Sinai and Director of the Voice Institute of New York. Dr. Koufman discusses the top considerations for helping prevent and treat reflux disease to help curb respiratory and other complications.
Host: Frank Russomano
Host Frank Russomano welcomes Rhondell Domilici, Regional Director for the Crohn's and Colitis Foundation, to discuss the organization's humble origins in 1967 as a small physician-patient collaborative, its rapid growth on a national scale, and the enduring mission that connects all past and present members.
Host: Barnett Mennen, MD
Physician Quality Reporting Systems, or PQRS, are here to stay in clinical medicine. Within the field of gastroenterology, understanding the metrics of PQRS can make a substantial difference in the success of a practice. Joining host Dr. Barry Mennen to detail the ins and outs of PQRS in gastroenterology is Dr. Ziad Gellad, Assistant Professor of Medicine, Director of Quality in the Division of Gastroenterology, and Director of Clinical Improvement in the Department of Medicine at Duke University Medical Center.
Host: Barnett Mennen, MD
Host Dr. Barry Mennen welcomes Dr. Ashwin Ananthakrishnan, Assistant Professor of Medicine at Harvard Medical School and medical co-director at the MGH Crohn’s and Colitis center. Dr. Ananthakrishnan is involved in several large cohort studies that are attempting to examine established and novel environmental factors, including diet, that influence the risk of development of inflammatory bowel diseases. His recent study focusing on the potential role of dietary zinc in preventing bowel inflammation becomes the focus of this discussion.
Host: Kathy King, RDN
Guest: Patsy Catsos
FODMAPs are short chain carbohydrates (oligosaccharides), disaccharides, monosaccharides and related alcohols that are poorly absorbed in the small intestine. For patients with irritable bowel syndrome, Celiac disease, or inflammatory bowel disorders, ingestion of these carbohydrates can significantly worsen disease symptoms. How are low FADMAP diets constructed to control this nutritional issue, and where do patients need help and guidance maintaining these diets?
Host Kathy King welcomes dietitian Patsy Catsos, author of IBS Free at Last. Ms. Catsos has a private practice in Portland, ME and has been an early adopter of the FODMAP approach for patients with functional bowel disorders.
Host: Jennifer Caudle, DO
Guest: Tasneem "Taz" Bhatia, MD
Dr. Jennifer Caudle welcomes Dr. Taz Bhatia, associate professor in Integrative Medicine at Emory University School of Medicine and and Founder and Medical Director of the Atlanta Center for Holistic and Integrative Medicine. Dr. Bhatia is author of The 21-Day Belly Fix: The Doctor-Designed Diet Plan for A Clean Gut and a Slimmer Waist. She describes her personal journey toward dual-expertise in allopathic and integrative medicine, and the research foundations behind her popular book.
Host: Matt Birnholz, MD
Dr. Matt Birnholz welcomes Patrick Higgins, President and Chief Operating Officer of Tekmira Pharmaceuticals, to discuss his research team's inspiring journey toward developing a cure for Hepatitis C. Following this success, Tekmira aims to accelerate the pace of research and development for a novel Hepatitis B drug.
Dr. Carol Burke, Director of the Center for Colon Polyp and Cancer Prevention at the Cleveland Clinic, unveils ongoing but underrecognized gender disparities in the practice of gastroenterology, such as differences in academic vs private practice opportunities, average salaries and hours worked, rates of promotion and partnerships, and male-modeled endoscopic equipment designs. Dr. Burke then explores gender disparities in GI care for patients with colorectal cancer, including differences in efficacy of colorectal cancer screening, male vs female morbidity and mortality rates, and even the underlying biologies of cancers themselves.
Irritable bowel syndrome is becoming increasingly recognized as a complex interplay of pathologies, from changes in gut microflora to nutrient absorption abnormalities to psychosocial stressors. The ways in which these factors contribute and interact create different profiles of disease, requiring personalized therapeutic plans for IBS patiets. Joining Dr. Barry Mennen to discuss a multimodal model for approaching the root causes of IBS is Dr. Neelesh A. Tipnis, the Paul H. Parker Professor and Chair of Pediatric Gastroenterology and Director of the GI Motility and Functional Bowel Disorders Program at the University of Mississippi Medical Center.
Live from the floor of Digestive Disease Week in Washington DC, GI Insights presents two interviews focusing on screening, surveillance, and therapeutic updates for colorectal and liver cancers, hosted by Dr. Barry Mennen. Guests on this program include:
-
Dr. Linda Rabeneck, Vice President of Prevention and Cancer Control at Cancer Care Ontario (CCO), Professor of Medicine at the University of Toronto, and Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES) in Toronto. Dr. Rabeneck speaks on global initiatives to increase awareness about colorectal cancer screening and surveillance.
-
Dr. Kris Kowdley, Director of the Liver Care Network and Research Director of the Organ Care Program at Swedish Medical Center in Seattle, WA. Dr. Kowdley summarizes key takeaways on recognition of liver cancer and other related diseases of the liver in American populations today.
Live from the floor of Digestive Disease Week in Washington DC, GI Insights presents two interviews focusing on innovative approaches to inflammatory bowel disease, hosted by Dr. Barry Mennen. Guests on this program include:
-
Dr. Jonathan Braun, Professor and Chair of Pathology and Lab Medicine at the David Geffen School of Medicine at UCLA. His research centers on the biology of mucosal interaction of host immunity with the local microbial community, and its impact on chronic mucosal inflammatory disease and cancer.
-
Michael Hurst, author of Poop Power: How a Man Used a Fecal Transplant at Home to Permanently Cure Himself of Ulcerative Colitis. Mr. Hurst is a known advocate and volunteer for the Fecal Transplant Foundation, whose story of self-designing an unorthodox treatment regimen for ulcerative colitis has since offered new insights on best clinical management practices for IBD.
Host Dr. Barry Mennen welcomes Dr. Ryan Stidham, Assistant Professor of Internal Medicine at the Inflammatory Bowel Diseases Center of the University of Michigan Health System, to discuss the current therapeutic landscape for IBD based on recent comparative clinical trials.
Host: Jay Goldstein, MD
Guest: Douglas Drossman, MD
Host Dr. Jay Goldstein discusses the latest in IBS & Functional GI Disorders (FGIDs) with guest expert Dr. Douglas Drossman of the Drossman Center for the Education and Practice of Integrated Care. Dr. Drossman is Professor Emeritus in the departments of Gastroenterology and Psychiatry at the Center for Functional GI and Motility, University of North Carolina at Chapel Hill.
Host Dr. Jay Goldstein welcomes Dr. Sunanda V. Kane, Professor of Medicine in the Department of Gastroenterology & Hepatology at Mayo Clinic, to dicuss the latest in Crohn's disease diagnosis and management. Dr. Kane is author of IBD Self-Management: The AGA Guide to Crohn's Disease and Ulcerative Colitis, now in its second edition.
```
```
Host: Brian P. McDonough, MD, FAAFP
Irritable Bowel Syndrome affects an estimated one out of ten people in the US, yet the causes for this disease are multivariate and often unknown from case to case, creating a reputation in practice as a "waste basket diagnosis." Dr. Michael Stierstorfer, Clinical Associate Professor of Dermatology at the University of Pennsylvania School of Medicine and founder of East Penn Dermatology, has been a pioneer in helping clinicians better understand one potential cause of IBS. His own experience as IBS patient led to the remarkable discovery of an allergic contact enteritits underscoring his disease, which has led to new diagnostic and treatment algorithms for IBS patients nationwide. Dr. Stierstorfer joins Dr. Brian McDonough to discuss this unexpected path toward discovery and subsequent career specialization.
Host: Brian P. McDonough, MD, FAAFP
A new therapy in the form of a vibrating pill-size capsule may help alleviate chronic idiopathic constipation without significant side effects. Joining Dr. Brian McDonough to discuss this innovative treatment method is Dr. Anish Sheth, practicing gastroenterologist at Princeton Medical Group in Princeton, NJ. And, to our listeners, please note that Dr. Sheth was not involved in the clinical trials of the investigational treatment mentioned in this interview.
Host: Ana Maria Rosario
Pancreatic Cancer strikes fear into the hearts of every practicing internist, pathologist, oncologist, and general surgeon on behalf of their patients, and unfortunately for us all, it’s on the rise. By 2030 it will be expected to climb to the number-2 spot for causes of cancer death. What new insights can we bring to the recognition and identification of pancreatic cancer to help curb that trend? Joining host Ana Maria Rosario at Omnia Education’s Stages in Women’s Health in New York is Dr. Aimee Lucas, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York.
Host: Lee Freedman, MD
Patients with ulcerative colitis often need to take multiple medications to achieve and sustain remission. But there is a pionering surgical approach, the laparoscopic J-pouch procedure, that can not only cure patients from this disease, but also eliminate risk of future colorectal cancer. Dr. Najia Mahmoud, Chief of the Division of Colon and Rectal Surgery and Associate Professor of Surgery at the Hospital of the University of Pennsylvania, joins Dr. Lee Freedman to discuss the risks and benefits of this procedure for patients with ulcerative colitis.
Host: Paul Rokuskie
Associations between autism and gastrointestinal health are being actively investigated in medical research. Two major projects, each spanning three years, are focusing in particular on intestinal bacteria, ie the microbiome, and constipation, respectively. Leading the charge on these investigations are Drs. Pat Levitt and James Versalovic. Dr. Levitt is Chair of Developmental Neurogenetics at Children's Hospital - Los Angeles (CHLA), while Dr. Versalovic is Chief of the Department of Pathology at Texas Children's Hospital. Their work seeks to better understand how the human microbiome impacts neural health and development, and how refined treatments aimed at changing this potential "gut/brain axis" may aid therapies for autism and other neurodevelopmental disorders.
The funding for the research project that Dr. Pat Levitt and Dr. James Versalovic are conducting is awarded by a grant from Autism Speaks.
Host: Lee Freedman, MD
Heated/Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is one of the most innovative treatments available today for complex abdominal cancers. What is it? Who is a candidate? And, what are the expected outcomes for our patients? Host Dr. Lee Freedman welcomes Dr. Giorgos Karakousis, Assistant Professor of Surgery at the Hospital of the University of Pennsylvania to discuss HIPEC.
Host: Prathima Setty, MD
According to the American Gastroenterological Association, gastroesophageal reflux disease (GERD) is the most common gastrointestinal diagnosis recorded on outpatient physician visits in the United States, which is remarkable considering the vagaries of the diagnosis. What are the symptoms and updated treatments for this common ailment, and how do physicians monitor for signs of progression to more serious disease states like Barrett's esophagus and esophageal cancer? Host Dr. Prathima Setty welcomes Dr. Anish Sheth, Director of Princeton University Medical Center's Esophageal Program, to help answer these and other questions.
Download and listen today!
Guest: Anthony J. Lembo, MD
Host: Brian P. McDonough, MD, FAAFP
Constipation is one of the most common problems encountered in general practice, and yet is all too often overlooked by physicians when patients are uncomfortable to mention it. How can clinicians best address this issue with reluctant patients, and what are the emerging therapies for chronic sufferers? Host Dr. Brian McDonough is joined by Dr. Anthony Lembo, Associate Professor of Medicine at Harvard Medical School and Director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center, to highlight updates in the management of constipation.
Guest: Mary Jane Minkin, MD
Host: Matt Birnholz, MD
Millions of insured women will have additional choices when it comes to their preferred method of birth control due to the Affordable Care Act for Women. But, what does that mean for health care providers and their patients?How does it change how patients are given treatment? Dr. Matt Birnholz welcomes Dr. Mary Jane Minkin. Dr. Minkin will address these questions and more. Dr. Minkin is a clinical professor of obstetrics and gynecology at Yale University School of Medicine and has a private practice in New Haven, Conn.
Host: Matt Birnholz, MD
ReachMD, in cooperation with HealthDay, Presents Conference Coverage of Digestive Disease Week 2011, held from May 7 to 10 in Chicago.
This year's meeting attracted approximately 15,000 participants from around the world, including researchers and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference featured approximately 5,000 abstracts and hundreds of lectures, highlighting recent advances in gastroenterology research, medicine, and technology.
Host: Aaron Carroll, MD
Guest: Rodrigo M. Vianna, MD
Multivisceral transplant entails the transplant of nearly all the abdominal organs, with the exception of the kidneys. It is a highly unusual procedure, with only about 30-40 such surgeries occurring per year in the United States, compared to thousands of liver transplants performed annually, in only about seven transplant centers in the United States. Host Dr. Aaron Carroll welcomes Dr. Rodrigo Vianna, director of intestinal and multivisceral transplant at Indiana University Health, to discuss when multivisceral transplant can be used to treat patients with rare tumors, such as neuroendorcrine or desmoid tumors.
Guest: Paul Kwo, MD
Host: Aaron Carroll, MD
Approximately three million people in the US have hepatitis C. In some cases, hepatitis C can be completely cured. However, many with the condition may be asymptomatic for decades and thus are not diagnosed until the disease has progressed into later stages. This is problematic, because when hepatitis C advances, it may cause scarring of the liver. When should liver transplant be considered for these patients? And what is the rate of recurrence and necessity for re-transplantation? Dr. Paul Kwo, medical director of the adult liver transplant program at Indiana University Health, discusses treatment options for patients with various stages of hepatitis C, as well as the evaluation process for those with advanced hepatitis C who are liver transplant candidates. Dr. Aaron Carroll hosts.
Host: Janet Wright, MD
Guest: Thad Waites, MD
Obesity is a nationwide epidemic, but this is nowhere more apparent than in Mississippi, which was ranked as the state with the highest obesity rate in 2009 by the Centers for Disease Control. How does the obesity issue in Mississippi mirror that of the rest of the nation, and what efforts are underway to address this public health problem? Dr. Thad Waites, director of the cardiac catheterization lab at Forrest General Hospital in Hattiesburg, Mississippi, and interventional cardiologist at the Hattiesburg Clinic, talks about how each player in the healthcare community can target the obesity epidemic. What initiatives and projects are demonstrating success in lowering obesity rates? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Julia Pallentino, MSN, JD, ARNP-BC
Host: Mimi Secor, DNP, FNP-BC, FAANP
Family nurse practitioners frequently see patients with gastrointestinal complaints. When can the family NP treat the patient, and when does the patient need to be referred to a GI specialist? Julia Pallentino, board certified nurse practitioner at GI Associates of Tallahassee in Tallahassee, Florida, discusses with host Mimi Secor common gastroenterological problems and their diagnostics and management. What can family NPs learn from the specialist about screening and treating gastroenterological conditions? On a related note, how can NPs convince the colonoscopy-phobic patient over 50 to begin colon cancer screening?
Guest: Diana Zuckerman, PhD
Host: Maurice Pickard, MD
The lap-band device dramatically reduces the size of a patient's stomach, and as such, it can be effective for weight loss in very obese patients. It offers at least one major advantage over gastric bypass surgery, in that the lap-band can be removed. But can the lap-band procedure also be safe and effective for patients who are even slightly obese, or do the potential risks outweigh the benefits for these patients? Dr. Diana Zuckerman, president of the National Research Center for Women & Families and its cancer prevention and treatment fund in Washington, D.C., discusses the criteria for patients to receive lap-banding. What concerns surround the issue of lowering the body-mass index (or BMI) threshold for patients eligible for this procedure? What are the long-term risks of lap-bands? Dr. Maurice Pickard hosts.
Host: Janet Wright, MD
Guest: Deepak Bhatt, MD
One of the biggest risks of antiplatelet therapy is gastrointestinal bleeding. Because of this risk, patients on the antiplatelet clopidogrel are often prescribed proten pump inhibitors, or PPIs. However, there are also concerns about PPIs decreasing the efficacy of clopidogrel. What approach should physicians take for patients at moderate to high risk for upper GI bleeding? Host Dr. Janet Wright welcomes Dr. Deepak Bhatt, chief of cardiology at the VA Boston Healthcare System, director of the Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital & VA Boston Healthcare System, and associate professor of medicine at Harvard Medical School, to discuss evidence about the potential interactions between PPIs and clopidogrel based on findings from the COGENT trial.
Produced in Cooperation with
Host: Matt Birnholz, MD
Listen for highlights from the American College of Gastroenterology's 75th Annual Scientific Meeting, October 15 - 20 in San Antonio, Texas. The meeting attracted approximately 4,000 participants from around the world. The meeting focused on advances in the management of patients with gastrointestinal disorders, focusing on cancer, esophageal and bowel disorders, liver disease, and pancreatic and biliary conditions.
Host: Jay Goldstein, MD
Guest: Jonathan Leighton, MD
Guest: Moshe Rubin, MD
Obscure gastrointesinal bleeding can pose investigational challenges. What are the potential causes of obscure GI bleeding? After initial negative upper endoscopy and colonoscopy tests are performed, what new technologies can help physicians more effectively detect small bowel abnormalities? Dr. Jonathan Leighton, professor of medicine and chair of the division of gastroenterology at the Mayo Clinic in Arizona, and Dr. Moshe Rubin, director of gastroenterology and program director of the GI fellowship training program at New York Hospital Queens Medical Center and the Weill-Cornell Medical College in New York, discuss the roles of small bowel capsule endoscopy, balloon-assisted enteroscopy, spiral enteroscopy, and CT enterography in evaluating patients with obscure GI bleeding. Dr. Jay Goldstein hosts.
Guest: Brian Lacy, MD, PhD
Host: Lee Freedman, MD
Resistance to proton pump inhibitors, or PPIs, is not uncommon among patients with gastroesophogeal reflux disease, or GERD. How should physicians initially approach managing patients with suspected GERD, and at what point should physicians classify a patient as a PPI non-responder? Our guest, Dr. Brian Lacy, associate professor of medicine at Dartmouth Medical School, and director of the GI Motility Laboratory at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, suggests tests that physicians might use in evaluating patients with refractory GERD, including upper endoscopy and various types of pH monitoring. What therapeutic strategies can physicians use to manage these patients? Hosted by Dr. Freedman.
Guest: Gary Falk, MD
Host: Lee Freedman, MD
Millions of Americans have esophageal disorders, ranging in severity from gastroesophogeal reflux (or GERD) to eosinophilic esophagitis to esophageal cancer. A diet rich in acidic or fatty foods can be to blame, but there are a number of other factors that may contribute to the development of GI disorders. When can physicians rely on empirical use of proton pump inhibitors, and when is endoscopy warranted? Dr. Gary Falk, professor of medicine in the division of gastroenterology at Penn Medicine, discusses some of the reasons for the increasing incidence of esophageal cancer and Barrett's esophagus in the U.S. What latest developments can help physicians optimally manage patients with these GI disorders? Dr. Falk also discusses the role of motility in acid reflux, and reviews current medication options for the condition. Dr. Lee Freedman hosts.
Produced in Cooperation with
Guest: Anthony Alessi, MD
Host: Matt Birnholz, MD
Host: Michael Greenberg, MD
In this show, our hosts get an update from ReachMD host Dr. Anthony Alessi, from Haiti, six months after the earthquake. And, they question Dr. Andrew Wakefield, widely-known for his controversial and discredited research linking the MMR vaccine with autism. He has a new book about his experiences, Callous Disregard: Autism and Vaccines: The Truth Behind a Tragedy.
Host: Lee Freedman, MD
Guest: Nuzhat Ahmad, MD
Although capsule endoscopy has been used since the start of the new millennium, the technology is still evolving and improving. Capsule endoscopy can help gastroenterologists visualize abnormalities in the small bowel, and offers many advantages over a traditional endoscopy, including less arduous preparation time. What are the common indications for capsule endoscopy, other than for obscure GI bleeding? Dr. Nuzhat Ahmad, assistant professor of medicine in the department of medicine and associate director of endoscopic services at Penn Medicine, also discusses the future of capsule endoscopy, and predicts that the next uses for the technology will allow the capsules to perform biopsies and provide injection therapies. Dr. Lee Freedman hosts.
Host: Mark Chyna, MD
Listen to the latest research findings presented at Digestive Disease Week 2010. This conference was held May 1-6 in New Orleans.
Guest: Francesco Rubino, MD
Host: Steven Edelman, MD
Gastrointestinal surgery for the morbid obese has long been an option in treatment, providing positive long-lasting results such as normal blood glucose and glycosylated hemoglobin levels and the discontinuation of diabetes-related medications. Is type 2 diabetes an operable intestinal disease? Join host Dr. Steven Edelman and his guest, chief of gastrointestinal metabolic surgery at Weill Cornell Medical College, Dr. Francesco Rubino, as they discuss the implications of metabolic surgery for type 2 patients.
Host: Mark Chyna, MD
These Conference Coverage Highlights are from the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium, held January 22nd to the 24th in Orlando, Florida. The meeting presented more than 500 abstracts on gastrointestinal cancers affecting the esophagus, stomach, hepatobiliary system, pancreas, small bowel, colon and rectum.
Guest: Bruce Buckingham, MD
Host: Steven Edelman, MD
The developing artificial pancreas carries tremendous potential for the treatment of diabetes. What is research telling us about the various steps to the implementation of the system? Join host Dr. Steven Edelman and his guest, pediatric endocrinologist and professor of medicine at Stanford University, Dr. Bruce Buckingham, as they discuss design, function, implementation, and obstacles to developing the artificial pancreas.
Host: Jay Goldstein, MD
Guest: Maria T. Abreu, MD
Dr. Maria Abreu, professor of medicine and chief of the division of gastroenterology at the University of Miami Miller School of Medicine, joins host Dr. Jay Goldstein to discuss inflammatory bowel disease, or IBD, and women's reproductive health. Does inflammatory bowel disease, or IBD, affect female fertility? What influence does IBD have on the course of pregnancy, and how does pregnancy, in turn, affect the natural history of IBD? Which medicines used to treat IBD are safe to use during pregnancy, and for new mothers who are nursing? Tune in to hear a discussion of these questions and more.
Guest: Rebecca West, JD
Host: Mark DeLegge, MD
The cost of malpractice insurance and the cost of resolving malpractice claims continues to climb. What are the trends in premiums for gastroenterologists around the country? And what are some of the most common risks and most commonly alleged errors? What’s the likelihood of a gastroenterologist being sued during his career? Rebecca West, CEO of Piedmont Liability Trust, a non-profit serving the University of Virginia School of Medicine, joins host Dr. Mark DeLegge to discuss strategies for avoiding malpractice claims. Ms. West also provides an update on national efforts at tort reform and how malpractice insurance premiums might be affected.
Guest: Miriam Vos, MD, MSPH
Host: Mark DeLegge, MD
Although it's important to consider the many factors that contribute to childhood obesity when designing a weight loss plan, sugar may be one of the most important components to target. Specifically, how does fructose influence childhood obesity? Dr. Miriam Vos, assistant professor in the department of gastroenterology at Emory University and author of the book The No-Diet Obesity Solution for Kids, published by the AGA Institute Press, offers tips for discussing a healthy lifestyle with parents of overweight children. Dr. Mark DeLegge hosts.
Host: Jay Goldstein, MD
Guest: Linda Lee, MD
How does delayed gastric emptying, or gastroparesis, affect patients? What are some of the common comorbid conditions of gastroparesis, and why are women and diabetic patients more susceptible? Dr. Linda Lee, clinical director of the division of gastroenterology and hepatology and director of the Johns Hopkins Integrative Medicine and Digestive Center at the Johns Hopkins University School of Medicine, reviews the best gastroparesis diagnostic tools and management strategies with host Dr. Jay Goldstein.
Guest: Alphonso Brown, MD, MS
Host: Mark DeLegge, MD
The causes of pancreatitis are often unknown, but we're learning that there are more potential causes than previously believed. Genetic causes are rare, but their detection has improved with new technology. What role might genetic testing play in correctly diagnosing and managing the condition? And what are the ramifications of genetic testing for the patient? Dr. Alphonso Brown, assistant professor of medicine at Harvard Medical School and co-director of the Pancreas Center at Beth Israel Deaconess Medical Center, joins host Dr. Mark DeLegge to discuss the application of genetics for patients with pancreatitis.
Guest: David Metz, MD
Host: Lee Freedman, MD
Although gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, are relatively common, they are often indolent. However, GEP-NETs can metastasize in a small portion of the population, so physicians should be aware of symptoms and screening tools. The two most common types of GEP-NETs are categorized as carcinoids and pancreatic endocrine tumors. What distinguishes the two? Host Dr. Lee Freedman welcomes Dr. David Metz, professor of medicine and associate chief for clinical affairs in the division of gastroenterology at Penn Medicine, to discuss characteristics and diagnosis of GEP-NETs.
Produced in Cooperation with
Guest: Barry Popkin, PhD
Host: Cathleen Margolin, PhD
Certain foods and beverages seem to go in and out of style as new research emerges to support or refute their health benefits. Yet when it comes to eating red meat, despite the long-standing advice from nutrition experts, our taste buds never seem to tire of the all-American burger or the juicy tenderloin steak. New research provides us with what is billed as definitive evidence that our penchant for red meat shortens our lifespan. Dr. Barry Popkin, the Carla Smith Chambliss Distinguished Professor of Global Nutrition and director of the Interdisciplinary Obesity Center at the University of North Carolina, joins host Dr. Cathleen Margolin to discuss how we can use this research, in addition to previous evidence on the subject, to encourage our patients to work toward healthier food habits.
Guest: James Wolosin, MD
Host: Steven Edelman, MD
Almost a third of all diabetics develop gastrointestinal complications specifically related to their diabetes. Host Dr. Steven Edelman is joined by his guest, gastroenterologist Dr. James Wolosin, senior staff physician at Sharp Healthcare San Diego, to discuss the treatment of gastroparesis, autonomic neuropathy and celiac disease.
Host: Matt Birnholz, MD
Over 15,000 gastrointestinal healthcare professionals attended the meeting in Chicago, May 30 - June 4, 2009. These highlights showcase the latest research and advances in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
Host: Jay Goldstein, MD
Guest: Christian Stone, MD, MPH
Incidents of Clostridium difficile, or C.diff, are increasing in the US. Are patients with ulcerative colitis or Crohn's disease more at risk for developing C. difficile infection than other patients? Is this due to an increased use of antibiotics in hospitals, or are other factors playing a role? Join host Dr. Jay Goldstein as he welcomes Dr. Christian Stone, associate professor of medicine at Washington University School of Medicine in St. Louis, to discuss the recent trends of C. difficile infections among inflammatory bowel disease patients.
Guest: Evelyn Hermes-DeSantis, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
Initial therapy for patients with gastroparesis often centers on dietary changes and pharmacotherapy. If first-line therapy proves ineffective, we appear to lack a broad selection of treatment options for patients with refractory gastroparesis. Some small studies have explored the idea that botulinum toxin could be valuable in this situation. What are its proposed mechanisms of action, and what is the current thinking on its efficacy? Host Dr. Charles Turck evaluates the evidence with Dr. Evelyn Hermes-DeSantis, director of the Drug Information Service at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, and a clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey.
Guest: Scott Waldman, MD, PhD
Host: Lee Freedman, MD
How is the biomarker guanylyl cyclase 2C helping to predict colorectal cancer recurrence rates? Host Dr. Lee Freedman welcomes Dr. Scott Waldman, professor in the departments of medicine and biochemistry at Thomas Jefferson University, to discuss how this biomarker found in regional lymph nodes can predict the recurrence rate for colorectal cancer patients. How does the presence of metastatic tumor cells predict clinical outcomes?
Guest: T. Karl Byrne, MD
Host: Mark DeLegge, MD
What are the advantages to each of the two main types of obesity surgeries— gastric bypass and lap band surgery? How do the recovery times, efficacy and potential complications compare? Host Dr. Mark DeLegge welcomes Dr. T. Karl Byrne, professor of surgery and medical director of the Bariatric Surgery Center at the Medical University of South Carolina, to discuss the role of the gastric bypass and lap band procedures in treating obesity. Are some patients clear candidates for one procedure over the other? And how is a third procedure — the sleeve gastrectomy — becoming another attractive option for treating obesity?
Guest: H. Richard Alexander, MD
Host: Mark Nolan Hill, MD
Whether cancer originates in the colon, breast, or elsewhere in the body, the liver is one of the most common places to which a malignancy will spread. When this occurs, if it's possible to control the metastasis in the liver, we may have a much better shot at holding the original tumor at bay. A technique called hepatic perfusion may help us do this. For more on hepatic perfusion and its potential role in the chemotherapeutic process, host Dr. Mark Nolan Hill talks with Dr. H. Richard Alexander, associate chairman for clinical research in the department of surgery at the University of Maryland School of Medicine. How might this technique, which affords us the opportunity to deliver high-dose therapy while circumventing most side effects, begin to change our perspective on the limitations of chemotherapeutics?
Guest: Miriam Vos, MD, MSPH
Host: Larry Kaskel, MD
Non-alcoholic fatty liver disease (NAFLD) is increasingly common among our young obese patients, a population for which cardiovascular disease and diabetes is a significant concern. Can measured levels of liver fat serve to help us gauge future risk for metabolic consequences in children? Host Dr. Larry Kaskel welcomes pediatric hepatologist, Dr. Miriam Vos, assistant professor in the division of gastroenterology at Emory University School of Medicine, to discuss the challenge of encouraging a young child and their family to develop habits that will promote the decline of the child's NAFLD. Dr. Vos also explores the possibility that body shape may be an important clue in the diagnosis of NAFLD, as well as current efforts to generate more accurate markers to quantify liver fat reduction during treatment.
Brought to you by:
Guest: Lisa Boardman, MD
Host: Mark DeLegge, MD
Early detection through screening for colorectal cancer (CRC) can make a huge impact in preventing the development or progression of CRC. What screening methods are most recommended? Dr. Lisa Boardman, assistant professor of medicine at the Mayo Clinic, reviews details of the CRC screening guidelines from both the Joint Effort Panel, as well as the United States Preventive Services Task Force. Will these guidelines be dramatically revised in the near future, and if so, will we shift towards widespread use of the newer CRC screening technologies? Dr. Mark DeLegge hosts.
Guest: J. Randolph Hecht, MD
Host: Jay Goldstein, MD
How have treatments for colorectal and pancreatic cancers advanced in recent years, and are novel treatments reducing the mortality rate of patients with these cancers? Dr. J. Randolph Hecht, director of the GI Oncology Program at the UCLA Health System and clinical professor of medicine in the hematology-oncology division at the UCLA David Geffen School of Medicine, looks at some of the newer pharmacological agents and methods being used to treat these gastrointestinal cancers. Dr. Jay Goldstein hosts.
Guest: Benjamin Griffith, MD
Host: Leslie P. Lundt, MD
What is the connection between anxiety and pancreatic cancer? Certainly, patients can develop problems with anxiety after a cancer diagnosis. But pancreatic cancer seems to have the curious characteristic of anxiety as a presenting symptom. The age at which anxiety presents itself may be a clue as to whether you're looking at mental illness or a possible cancer diagnosis. Dr. Benjamin Griffith, assistant professor of medicine at the University of Virginia and the Edward Via Virginia College of Osteopathic Medicine, explains to host Dr. Leslie Lundt.
Guest: Michael Camilleri, MD
Host: Mark DeLegge, MD
What are some of the newer bariatric endoscopic procedures, and when are these procedures preferred over traditional gastric bypass surgery? Dr. Michael Camilleri, professor of medicine and physiology at the Mayo Clinic Medical School in Rochester, Minnesota, reviews the most common gastric bypass procedures, such as the Roux-en-Y, laproscopic banding and duodenal switch procedures, and explains the advantages to some of the newer surgeries, including the sleeve gastrectomy and transoral gastroplasty. Dr. Mark DeLegge hosts.
Guest: Emmet Keeffe, MD
Host: Jay Goldstein, MD
What do recent measures recommend to primary care physicians and gastroenterologists who care for patients with hepatitis C? Dr. Emmet Keeffe, professor of medicine emeritus at Stanford University Medical Center, joins host Dr. Jay Goldstein to outline the 10 measures for diagnosing and treating patients with hepatitis C.
Guest: Marc Bessler, MD
Host: Mark Nolan Hill, MD
As the field of bariatric and minimally invasive surgery continues to grow, the gastric bypass procedure has grabbed many of the headlines, with solid interest in gastric banding as well. Looking ahead, how might the landscape change? Will a new bariatric procedure emerge as the safest and most effective choice? Host Dr. Mark Nolan Hill welcomes Dr. Marc Bessler, assistant professor of surgery at Columbia University College of Physicians and Surgeons, and director of the Columbia University Center for Metabolic and Weight Loss Surgery, to detail one procedure that could represent the next step in reducing the invasiveness of bariatric surgery: the transoral gastroplasty.
Guest: David Peura, MD
Host: Mark DeLegge, MD
Constipation is a common symptom that presents more often in women and as patients get older. What are the primary and secondary causes of chronic constipation? What are some of the differentiating factors between chronic constipation and IBS-C? Dr. David Peura, professor of medicine at the University of Virginia School of Medicine, joins host Dr. Mark DeLegge to discuss algorithms for diagnosing chronic constipation. When are lifestyle changes not enough for treating chronic constipation, and what are the most effective alternatives?
Guest: Scott Cotler, MD
Host: Jay Goldstein, MD
Untreated hepatitis B can lead to cirrhosis and liver cancer. What methods are available for physicians to treat hepatitis B patients? Host Dr. Jay Goldstein reviews available treatments for reducing liver damage from hepatitis B with Dr. Scott Cotler, chief of hepatology at the University of Illinois at Chicago. How can the virus be suppressed while reducing the progression of liver disease?
Guest: David Sarwer, PhD
Host: Leslie P. Lundt, MD
Understanding the psychosocial aspects of treating morbid obesity may help us improve the success rate of these patients postoperatively. Dr. David Sarwer, the director of clinical services at the Center for Weight and Eating Disorders at the University of Pennsylvania School of Medicine, explores the psychological workup of the pre-op bariatric surgery patient with host Dr. Leslie Lundt.
Host: Mark DeLegge, MD
Guest: William J. Sandborn, MD
The current treatment paradigm for Crohn's disease is a pyramid approach, where patients are given the safest medications before pursuing more aggressive strategies. New evidence suggests that Crohn's disease should be treated with the most effective medications first, such as anti-TNF therapies. But is a top-down strategy safe enough for most patients? Dr. William Sandborn, professor of medicine and gastrointestinal research at Mayo Clinic College of Medicine, describes the results of new Crohn's disease trials and research. Is using steroids to treat Crohn's disease an idea of the past, or are steroids still effective for certain patients? Dr. Mark DeLegge hosts.
Guest: Jonathan Spergel, MD, PhD
Host: Todd Mahr, MD
One of the most common and frequently misdiagnosed eosinophilic gastrointestinal diseases is eosinophilic esophagitis. When should a physician suspect eosinophilic esophagitis, and how can it be accurately diagnosed? How significant a factor is diet in such disorders? Dr. Jonathan Spergel, associate professor of pediatrics at the University of Pennsylvania School of Medicine, delves into the potential causes of eosinophilic gastrointestinal diseases with host Dr. Todd Mahr.
Guest: Brennan Spiegel, MD, MSHS
Host: Jay Goldstein, MD
In its 1948 charter constitution, the World Health Organization defined health as "a state of complete physical, mental and social well-being." Today, to measure this totality of well-being, we measure quality of life. Host Dr. Jay Goldstein discusses how quality of life measurements can be incorporated into everyday practice, with Dr. Brennan Spiegel, assistant professor of medicine in the division of digestive diseases at the David Geffen School of Medicine at UCLA. How is health-related quality of life measured objectively in clinical trials? To what degree do quality of life endpoints trump physiological endpoints?